0000897101-24-000163.txt : 20240507 0000897101-24-000163.hdr.sgml : 20240507 20240507163059 ACCESSION NUMBER: 0000897101-24-000163 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 49 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Electromed, Inc. CENTRAL INDEX KEY: 0001488917 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 411732920 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-34839 FILM NUMBER: 24922515 BUSINESS ADDRESS: STREET 1: 500 SIXTH AVENUE NW CITY: NEW PRAGUE STATE: MN ZIP: 56071 BUSINESS PHONE: 952-758-9299 MAIL ADDRESS: STREET 1: 500 SIXTH AVENUE NW CITY: NEW PRAGUE STATE: MN ZIP: 56071 10-Q 1 elmd240512_10q.htm 10-Q FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q
(Mark One)
☑	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended March 31, 2024

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from to .

Commission File No.: 001-34839

Electromed, Inc.

(Exact Name of Registrant as Specified in its Charter)

Minnesota		41-1732920
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

500 Sixth Avenue NW New Prague, Minnesota		56071
(Address of principal executive offices)		(Zip Code)

(952) 758-9299

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.01 par value		ELMD		NYSE American LLC
(Title of each class)		(Trading Symbol(s))		(Name of each exchange on which registered)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☑ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☑	Smaller reporting company ☑

	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑

There were 8,655,727 shares of Electromed, Inc. common stock, par value $0.01 per share, outstanding as of the close of business on May 2, 2024.

Electromed, Inc.

Index to Quarterly Report on Form 10-Q

		Page

PART I – FINANCIAL INFORMATION
	Item 1. Financial Statements	1
	Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations	11
	Item 3. Quantitative and Qualitative Disclosures About Market Risk.	17
	Item 4. Controls and Procedures	17

PART II – OTHER INFORMATION
	Item 1. Legal Proceedings	17
	Item 1A. Risk Factors	17
	Item 2. Unregistered Sales of Equity Securities and Use of Proceeds	17
	Item 3. Defaults Upon Senior Securities	17
	Item 4. Mine Safety Disclosures	18
	Item 5. Other Information	18
	Item 6. Exhibits	18

PART I – FINANCIAL INFORMATION

Item 1.

Financial Statements.

Electromed, Inc.

Condensed Balance Sheets

	March 31, 2024		June 30, 2023
	(Unaudited)
Assets
Current Assets
Cash and cash equivalents	$	11,712,000	$	7,372,000
Accounts receivable (net of allowances for credit losses of $45,000)		23,907,000		24,130,000
Contract assets		642,000		487,000
Inventories		4,178,000		4,221,000
Prepaid expenses and other current assets		592,000		1,577,000
Income tax receivable		291,000		-
Total current assets		41,322,000		37,787,000
Property and equipment, net		5,283,000		5,672,000
Finite-life intangible assets, net		648,000		605,000
Other assets		106,000		161,000
Deferred income taxes		1,542,000		1,581,000
Total assets	$	48,901,000	$	45,806,000

Liabilities and Shareholders' Equity
Current Liabilities
Accounts payable	$	792,000	$	1,372,000
Accrued compensation		2,987,000		3,018,000
Income tax payable		-		336,000
Warranty reserve		1,525,000		1,378,000
Other accrued liabilities		1,022,000		1,949,000
Total current liabilities		6,326,000		8,053,000
Other long-term liabilities		31,000		86,000
Total liabilities		6,357,000		8,139,000

Commitments and Contingencies

Shareholders’ Equity
Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,655,727 and 8,555,238 shares issued and outstanding, as of March 31, 2024, and June 30, 2023, respectively		87,000		86,000
Additional paid-in capital		20,342,000		18,788,000
Retained earnings		22,115,000		18,793,000
Total shareholders' equity		42,544,000		37,667,000
Total liabilities and shareholders' equity	$	48,901,000	$	45,806,000

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Condensed Statements of Operations (Unaudited)


	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Net revenues	$	13,871,000	$	12,068,000	$	39,884,000	$	34,455,000
Cost of revenues		3,489,000		3,012,000		9,459,000		8,386,000
Gross profit		10,382,000		9,056,000		30,425,000		26,069,000

Operating expenses
Selling, general and administrative		8,374,000		7,694,000		25,699,000		22,937,000
Research and development		167,000		166,000		480,000		618,000
Total operating expenses		8,541,000		7,860,000		26,179,000		23,555,000
Operating income		1,841,000		1,196,000		4,246,000		2,514,000
Interest income, net		120,000		26,000		293,000		37,000
Net income before income taxes		1,961,000		1,222,000		4,539,000		2,551,000

Income tax expense		468,000		147,000		1,217,000		418,000

Net income	$	1,493,000	$	1,075,000	$	3,322,000	$	2,133,000

Income per share:

Basic	$	0.17	$	0.13	$	0.39	$	0.25

Diluted	$	0.17	$	0.12	$	0.38	$	0.25

Weighted-average common shares outstanding:
Basic		8,565,725		8,461,531		8,549,352		8,449,623
Diluted		8,892,821		8,710,106		8,822,938		8,694,407

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Condensed Statements of Cash Flows (Unaudited)


	Nine Months Ended March 31,
	2024			2023
Cash Flows From Operating Activities
Net income	$	3,322,000		$	2,133,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation		594,000			370,000
Amortization of finite-life intangible assets		37,000			52,000
Share-based compensation expense		1,250,000			506,000
Deferred income taxes		39,000			32,000
Changes in operating assets and liabilities:
Accounts receivable		223,000			(1,293,000	)
Contract assets		(155,000	)		(284,000	)
Inventories		78,000			(264,000	)
Prepaid expenses and other assets		1,234,000			105,000
Income tax receivable, net		(627,000	)		(270,000	)
Accounts payable and accrued liabilities		(1,386,000	)		(111,000	)
Accrued compensation		(31,000	)		(660,000	)
Net cash provided by operating activities		4,578,000			316,000

Cash Flows From Investing Activities
Expenditures for property and equipment		(265,000	)		(1,221,000	)
Expenditures for finite-life intangible assets		(84,000	)		(54,000	)
Net cash used in investing activities		(349,000	)		(1,275,000	)

Cash Flows From Financing Activities
Issuance of common stock upon exercise of options		111,000			40,000
Taxes paid on net share settlement of stock option exercises		-			(305,000	)
Repurchase of common stock		-			(153,000	)
Net cash provided by (used in) financing activities		111,000			(418,000	)
Net increase (decrease) in cash		4,340,000			(1,377,000	)
Cash and cash equivalents
Beginning of period		7,372,000			8,153,000
End of period	$	11,712,000		$	6,776,000

Supplemental Disclosures of Cash Flow Information
Cash paid for income taxes	$	1,806,000		$	655,000

Supplemental Disclosures of Noncash Investing and Financing Activities
Property and equipment acquisitions in accounts payable	$	35,000		$	136,000
Intangible asset acquisitions in accounts payable	$	-		$	6,000
Option exercise proceeds in other assets	$	194,000		$	-
Demonstration equipment returned to inventory	$	35,000		$	9,000

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Condensed Statements of Shareholders’ Equity (Unaudited)


	Common Stock					Additional Paid-			Retained			Total Shareholders’
	Shares			Amount		in Capital			Earnings			Equity
Balance on June 30, 2022		8,475,438		$	85,000	$	18,308,000		$	15,780,000		$	34,173,000
Net income		–			–		–			81,000			81,000
Issuance of restricted stock		27,400			–		–			–			–
Forfeiture of restricted stock		(14,166	)		–		–			–			–
Issuance of common stock upon exercise of options		11,760			–		–			–			–
Taxes paid on stock options exercised on a net basis		–			–		(60,000	)		–			(60,000	)
Share-based compensation expense		–			–		95,000			–			95,000
Repurchase of common stock		(14,568	)		–		–			(145,000	)		(145,000	)
Balance on September 30, 2022		8,485,864			85,000		18,343,000			15,716,000			34,144,000

Net income		–			–		–			977,000			977,000
Issuance of restricted stock		26,000			–		–			–			–
Issuance of common stock upon exercise of options		3,100			–		16,000			–			16,000
Share-based compensation expense		–			–		221,000			–			221,000
Repurchase of common stock		(800	)		–		–			(8,000	)		(8,000	)
Balance at December 31, 2022		8,514,164		$	85,000	$	18,580,000		$	16,685,000		$	35,350,000

Net income		–			–		–			1,075,000			1,075,000
Issuance of common stock upon exercise of options		42,436			1,000		23,000			–			24,000
Taxes paid on stock options exercised on a net basis		–			–		(245,000	)		–			(245,000	)
Share-based compensation expense		–			–		190,000			–			190,000
Balance on March 31, 2023		8,556,600		$	86,000	$	18,548,000		$	17,760,000		$	36,394,000


	Common Stock				Additional Paid-		Retained		Total Shareholders’
	Shares		Amount		in Capital		Earnings		Equity
Balance on June 30, 2023		8,555,238	$	86,000	$	18,788,000	$	18,793,000	$	37,667,000
Net income		–		–		–		155,000		155,000
Issuance of restricted stock		20,878		–		–		–		–
Issuance of common stock upon exercise of options		2,934		–		29,000		–		29,000
Share-based compensation expense		–		–		371,000		–		371,000
Balance on September 30, 2023		8,579,050		86,000		19,188,000		18,948,000		38,222,000

Net income		–		–		–		1,674,000		1,674,000
Issuance of restricted stock		21,000		–		–		–		–
Issuance of common stock upon exercise of options		2,627		–		26,000		–		26,000
Share-based compensation expense		–		–		420,000		–		420,000
Balance on December 31, 2023		8,602,677	$	86,000	$	19,634,000	$	20,622,000	$	40,342,000

Net income		–		–		–		1,493,000		1,493,000
Issuance of restricted stock		2,550		–		–		–		–
Issuance of common stock upon exercise of options		50,500		1,000		249,000		–		250,000
Share-based compensation expense		–		–		459,000		–		459,000
Balance on March 31, 2024		8,655,727	$	87,000	$	20,342,000	$	22,115,000	$	42,544,000

See Notes to Condensed Financial Statements (Unaudited).

Electromed, Inc.

Notes to Condensed Financial Statements (Unaudited)

Note 1. Interim Financial Reporting

Nature of business: Electromed, Inc. (the “Company”) develops, manufactures, and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy for pulmonary care patients. The Company markets its products in the U.S. to the homecare and hospital markets. The Company also sells internationally through distributors.

Since its inception, the Company has operated in a single industry segment: developing, manufacturing, and marketing medical equipment.

Basis of presentation: The accompanying unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (“fiscal 2023”).

A summary of the Company’s significant accounting policies follows:

Use of estimates. Management uses estimates and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation and warranty reserve.

Net income per common share. Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were 289,362 and 179,992 for the three months ended March 31, 2024, and 2023, respectively, and were 400,639 and 200,140 for the nine months ended March 31, 2024, and 2023, respectively.

Recently Issued Accounting Standards

In June 2016, the Financial Accounting Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments -- Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. The company adopted the standard effective July 1, 2023. The Company’s adoption of the standard did not have a material impact on the financial statements.

Note 2. Revenues

Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including consideration paid or payable from customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under Performance obligations and transaction price.

Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs” (“ASC 340”), or other applicable guidance are met.

The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of the Company’s SmartVest® Airway Clearance System (“SmartVest System”) after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues in the Condensed Statements of Operations.

The timing of revenue recognition, billings and cash collections results in accounts receivable on the Condensed Balance Sheets as further described below under Accounts receivable and Contract assets.

Disaggregation of revenues. In the following table, net revenues are disaggregated by market:

Schedule of disaggregated revenue

	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Homecare	$	12,287,000	$	10,971,000	$	36,108,000	$	31,335,000
Hospital		783,000		440,000		1,909,000		1,420,000
Homecare distributor		524,000		501,000		1,377,000		1,391,000
Other		277,000		156,000		490,000		309,000
Total	$	13,871,000	$	12,068,000	$	39,884,000	$	34,455,000

In the following table, net homecare revenue is disaggregated by payer type:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Commercial	$	5,974,000	$	4,787,000	$	17,684,000	$	12,706,000
Medicare		4,825,000		4,544,000		13,666,000		13,753,000
Medicare Supplemental		1,177,000		1,278,000		3,447,000		3,681,000
Medicaid		115,000		128,000		722,000		618,000
Other homecare		196,000		234,000		589,000		577,000
Total	$	12,287,000	$	10,971,000	$	36,108,000	$	31,335,000

Revenues are recognized at a point in time when control passes to the customer upon product shipment or delivery.

Performance obligations and transaction price. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations and the timing or method of revenue recognition in each of the Company’s markets are discussed below:

Homecare market. In the Company’s homecare market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised of three main components – a generator, a vest and a connecting hose – that are sold together as an integrated unit. Accordingly, in contracts within the homecare market, the Company regards the SmartVest System to be a single performance obligation.

The Company makes available to its homecare patients limited post-sale services that are not material in the context of the contracts, either individually or taken together, and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed when the related revenues are recognized. As such, transactions in the homecare market consist of a single performance obligation: the SmartVest System.

Homecare patients generally will rely on third-party payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers’ reimbursement programs fall into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or (iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues to use the SmartVest System.

Regardless of the type of transaction, provided criteria for an enforceable contract are met, it is the Company’s long- standing business practice to regard all homecare agreements as transferring control to the patient upon shipment or delivery, despite possible payment cancellation under government or commercial programs where the payer is controlling the payment over specified time periods. For homecare sales that feature installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly less than expected if the contract is terminated due to changes in the patient’s status, including insurance coverage, hospitalization, death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System, the patient is under no obligation to return the SmartVest System should payments be terminated because of the described contingencies. As a result, the Company’s product sales qualify for point-in-time revenue recognition. Control transfers to the patient, and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further discussed under Accounts receivable and Contract assets below.

The Company’s contractually stated transaction prices in the homecare market are generally set by the terms of the contracts negotiated with insurance companies or by government programs. The transaction price for the Company’s products may be further impacted by variable consideration. ASC 606 requires the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value of payments to be received from insurance payers based on historical experience and other available information, subject to the constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include (i) capped installment payments, which are subject to the third-party payer’s termination due to changes in insurance coverage, death or the patient’s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility amounts for deductibles, coinsurance, copays and other similar payments.

Although estimates may be made on a contract-by-contract basis, whenever possible, the Company uses all available information, including historical collection patterns, to estimate variable consideration for portfolios of contracts. The Company’s estimates of variable consideration consist of amounts it may receive from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the payment duration, changes to a patient’s insurance status, changes in an insurance allowable, claims in appeals with Medicare and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur.

For example, for contracts in which the Company believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration are generally not subject to the risk of significant revenue reversal.

For each type of variable consideration discussed above, there are many contracts with similar characteristics with a wide range of possible transaction prices. For that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration.

The Company often receives payment from third-party payers for SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs; the fundamental purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a short period of time.

Homecare distributors. Sales to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor’s purchases accumulate to give the distributor the right to a higher discount on purchases more than the specified level within the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to the distributor, as applicable.

Hospital market. The Company’s hospital sales are made to hospitals and other clinics. Sales to these hospitals are negotiated with the individual hospital or with group purchasing organizations, with payments received directly from the hospital. No insurance reimbursement is involved. Generators are either sold or leased to the hospitals and associated hoses and wraps (used in hospital settings rather than vests) are sold separately. Accordingly, each product is distinct and considered a separate performance obligation in sales to hospital customers. The agreements with hospitals fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments:

●

Outright sale – Under these transactions, the Company sells its products for a prescribed or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and payment is made within normal credit terms, usually within thirty days.

●

Wrap usage agreements – Under these transactions, the Company provides a generator device at no cost to the hospital in return for a fixed annual commitment to purchase consumable wraps. These agreements are cancellable upon at least sixty days prior written notice by either party. If cancelled, the generator is returned to the Company, where it can be refurbished and used again later. Revenue for the consumable wraps is recognized when control transfers to the customer.

Other. Other revenue consists of international sales which are made directly to several independent distributors at fixed contract prices that are not subject to further adjustments for variable consideration or sales to other customers that do not fall into the markets described above. Transfer of control of the products occurs upon shipment or delivery to the distributor or customer, as applicable.

Product warranty. The Company offers warranties on its products. These warranties are assurance-type warranties not sold on a standalone basis or are otherwise considered immaterial in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold.

Accounts receivable. The Company’s accounts receivable balance is comprised of amounts due from individuals, -hospitals, and distributors. Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid, and private insurance companies. Accounts receivables are carried at amounts estimated to be received from patients under reimbursement arrangements with third-party payers. Accounts receivable is also net of an allowance for credit losses. Management determines the allowance for credit losses by regularly evaluating individual customer accounts and determining expected losses.

Contract assets. Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional.

Contract balances. The following table provides information about contract assets from contracts with customers:

Schedule of contract asset

	Nine Months Ended March 31, 2024			Fiscal Year Ended June 30, 2023
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	487,000		$	286,000
Reclassification of contract assets to accounts receivable		(1,453,000	)		(1,220,000	)
Contract assets recognized		1,829,000			1,351,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(221,000	)		70,000
Contract assets, ending	$	642,000		$	487,000

Incremental costs to obtain a contract. Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expenses sales incentives as incurred. These costs are included in selling, general and administrative expenses in the Condensed Statements of Operations.

Note 3. Inventories

The components of inventory were as follows:

	March 31, 2024			June 30, 2023
Parts inventory	$	3,016,000		$	3,420,000
Work in process		449,000			470,000
Finished goods		856,000			323,000
Estimated inventory to be returned		260,000			265,000
Less: Reserve for obsolescence		(403,000	)		(257,000	)
Total	$	4,178,000		$	4,221,000

Note 4. Warranty Reserve

The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all hospital sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty reserve include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty reserve and adjusts the amounts as necessary.

Changes in the Company’s warranty reserve were as follows:

	Nine Months Ended March 31, 2024			Fiscal Year Ended June 30, 2023
Warranty reserve, beginning	$	1,378,000		$	1,256,000
Accrual for products sold		426,000			416,000
Expenditures and costs incurred for warranty claims		(279,000	)		(294,000	)
Warranty reserve, ending	$	1,525,000		$	1,378,000

Note 5. Income Taxes

Income tax expense was estimated at $468,000 and $1,217,000, and the effective tax rate was 23.9% and 26.8% for the three and nine months ended March 31, 2024, respectively. Estimated income tax expense for the three and nine months ended March 31, 2024, includes a discrete current tax benefit of $99,000 and $95,000, respectively, primarily related to the exercise of stock options.

Income tax expense was estimated at $147,000 and $418,000, and the effective tax rate was 12.0% and 16.4% for the three and nine months ended March 31, 2023, respectively. Estimated income tax expense for the three and nine months ended March 31, 2023, includes a discrete current tax benefit of $176,000 and $219,000, respectively, related to the exercise of stock options.

The Company is subject to U.S. federal and state income tax in multiple jurisdictions. With limited exceptions, years prior to the Company’s fiscal year ended June 30, 2020, are no longer open to U.S. federal, state or local examinations by taxing authorities. The Company is not under any current income tax examinations by any federal, state or local taxing authority. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs.

Note 6. Financing Arrangements

The Company has a credit facility that provides for a $2,500,000 revolving line of credit through December 18, 2025, if not renewed before such date. There was no outstanding principal balance on the line of credit as of March 31, 2024, or June 30, 2023. Interest on borrowings under the line of credit, if any, accrues at the prime rate (8.50% on March 31, 2024) less 1.00% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable. On March 31, 2024, the maximum $2,500,000 was eligible for borrowing. Payment obligations under the line of credit, if any, are secured by a security interest in substantially all the tangible and intangible assets of the Company.

The documents governing the line of credit contain certain financial and non-financial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends.

Note 7. Common Stock

Authorized shares: The Company’s Articles of Incorporation, as amended, have established 15,000,000 authorized shares of capital stock consisting of 13,000,000 shares of common stock, par value $0.01 per share, and 2,000,000 shares of undesignated stock.

On May 26, 2021, the Company’s Board of Directors (the “Board”) approved a stock repurchase authorization. Under the authorization, the Company was originally able to repurchase up to $3.0 million of shares of common stock through May 26, 2022. On May 26, 2022, the Board removed the date limitation. As of March 31, 2024, a total of 239,995 shares have been repurchased and retired under this authorization for a total cost of $2,725,000, or $11.36 per share. Repurchased shares have been retired and constitute authorized but unissued shares. There were no share repurchases for the three and nine months ended March 31, 2024.

Note 8. Share-Based Compensation

The Company’s share-based compensation plans are described in Note 8 to the financial statements included in the Company’s Annual Report on Form 10-K for fiscal 2023. Share-based compensation expense was $1,250,000 and $506,000 for the nine months ended March 31, 2024, and 2023, respectively. This expense is included in selling, general and administrative expense in the Condensed Statements of Operations.

Stock Options

Stock option transactions during the nine months ended March 31, 2024, are summarized as follows:

	Number of Shares			Weighted-Average Exercise Price per Share
Outstanding on June 30, 2023		451,570		$	6.93
Granted		263,162		$	10.70
Exercised		(56,063	)	$	5.45
Cancelled or Forfeited		(21,079	)	$	10.46
Outstanding on March 31, 2024		637,590		$	8.50

The following assumptions were used to estimate the fair value of stock options granted:

	Nine Months Ended March 31, 2024	Fiscal Year Ended June 30, 2023
Risk-free interest rate	3.85 – 4.64%	2.88 - 4.23%
Expected term (years)	6	6
Expected volatility	51 - 53%	53% - 54%

The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. On March 31, 2024, the weighted average remaining contractual term for all outstanding stock options was 6.7 years and the aggregate intrinsic value of the options was $4,878,000. Outstanding on March 31, 2024, were 637,590 stock options issued to employees, of which 319,088 were vested and exercisable and had an aggregate intrinsic value of $3,118,000. As of March 31, 2024, $925,000 of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted-average period of approximately 2.8 years.

Restricted Stock

During the nine months ended March 31, 2024, the Company issued restricted stock awards to employees totaling 23,428 shares of common stock, with a weighted average vesting term of 3.0 years and a weighted average fair value of $10.74 per share, and to directors totaling 21,000 shares of common stock, with a vesting term of six months and a weighted average fair value of $10.44 per share. There were 57,661 shares of unvested restricted stock with a weighted average fair value of $10.53 per share outstanding as of March 31, 2024. As of March 31, 2024, $253,000 of total unrecognized compensation expense related to restricted stock awards is expected to be recognized over a weighted-average period of approximately 1.6 years.

Performance-Based Restricted Stock Units

The Company granted 175,000 performance-based restricted stock units (“PSUs”) to our CEO in connection with his appointment as CEO on July 1, 2023. The PSUs are to be earned based on the extent to which performance goals tied to Total Shareholder Return (“TSR”) are achieved. The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. The grant date fair value of the awards was determined using a Monte Carlo valuation model with an expected term of four years.

Stock based compensation expense recognized for PSUs was $217,000 and $0 for the nine months ended March 31, 2024, and 2023, respectively. The weighted average grant date fair value per unit was $6.58 and as of March 31, 2024, there are 175,000 PSUs outstanding. On March 31, 2024, there was approximately $935,000 of total unrecognized compensation expense related to outstanding PSUs that is expected to be recognized over a period of 3.25 years.

Note 9. Commitments and Contingencies

The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other disposition.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited Condensed Financial Statements and related notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q, and our audited financial statements and related notes thereto included in Part II, Item 8 of our Annual Report on Form 10-K for the fiscal year ended June 30, 2023 (“fiscal 2023”).

Overview

Electromed, Inc. (“we,” “our,” “us,” “Electromed” or the “Company”) develops and provides innovative airway clearance products applying High Frequency Chest Wall Oscillation (“HFCWO”) technologies in pulmonary care for patients.

We manufacture, market, and sell products that provide HFCWO, including the SmartVest® Airway Clearance System (“SmartVest System”) that includes our newest generation SmartVest Clearway® Airway Clearance System (“Clearway”), previous generation SmartVest SQL®, and related garments and accessories to patients with compromised pulmonary function. The SmartVest Clearway, which received 510(k) clearance from the U.S. Food and Drug Administration in December 2022, provides patients with proven quality of life outcomes while offering a state-of-the-art patient experience with a simple touch screen user interface, small footprint and lightest HFCWO generator on the market.

Our products are sold in both the homecare market and the hospital market for inpatient use, which we refer to as “hospital sales.” Since 2000, we have marketed the SmartVest System and its predecessor products to patients suffering from bronchiectasis, cystic fibrosis, and other chronic pulmonary conditions which require external chest manipulation to enhance mucus transport. Additionally, we offer our products to a patient population that includes neuromuscular disorders such as cerebral palsy, muscular dystrophies, amyotrophic lateral sclerosis (“ALS”), patients with post-surgical complications or who are ventilator dependent and patients who have other conditions involving excess secretion and impaired mucus transport.

The SmartVest System is often eligible for reimbursement from major private insurance providers, health maintenance organizations (“HMOs”), state Medicaid systems, and the federal Medicare system, which we believe is an important consideration for patients considering an HFCWO course of therapy. For domestic sales, the SmartVest System may be reimbursed under the Medicare-assigned billing code (E0483) for HFCWO devices if the patient has cystic fibrosis, bronchiectasis (including chronic bronchitis or COPD that has resulted in a diagnosis of bronchiectasis), or any one of certain enumerated neuromuscular diseases and myopathies and can demonstrate that another less expensive physical or mechanical treatment did not adequately mobilize retained secretions. Private payers consider a variety of sources, including Medicare, as guidelines in setting their coverage policies and payment amounts.

Critical Accounting Estimates

For a description of our critical accounting estimates and assumptions used in the preparation of our financial statements, including the unaudited Condensed Financial Statements in this Quarterly Report on Form 10-Q, see Note 1 and Note 2 to our unaudited Condensed Financial Statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q and Part II, Item 7, and Note 1 to our audited financial statements included in Part II, Item 8, of our Annual Report on Form 10-K for fiscal 2023.

There were no material changes in our critical accounting estimates and assumptions since the filing of our Annual Report on Form 10-K for fiscal 2023.

Change Healthcare Update

In late February 2024, UnitedHealth Group’s Change Healthcare was impacted by a cybersecurity incident, negatively impacting financial operations for hospitals, insurers, pharmacies, and medical groups nationwide. Change Healthcare is a financial clearinghouse that works across the health system to make clinical, administrative and financial processes simpler and more efficient for payers, providers and consumers.

Electromed had historically filed all non-Medicare claims through Change Healthcare’s clearinghouse. However, we resolved nearly 75% of our delayed claims by the end of the quarter with successful submissions through an alternate clearinghouse. Although we experienced an approximately three-week delay in non-Medicare claims submissions, our impact to cashflow was less than $1,000,000 for the quarter ended March 31, 2024, and is expected to fully resolve by the end of the current fiscal year, June 30, 2024. In spite of this headwind, we finished the quarter ended March 31, 2024 with $11,712,000 of cash, a $1,278,000 improvement from our prior quarter ($10,434,000 for the quarter ended December 31, 2023).

Although we were able to adapt quickly to mitigate the direct impacts of the Change Healthcare cyberattack on our business and operations future disruptions through Change Healthcare or any other financial clearinghouse could have a material adverse impact on our cash flow and ultimate ability to receive payment on our claims.

Results of Operations

Net Revenues

Net revenues for the three and nine months ended March 31, 2024, and 2023 are summarized in the table below.

	Three Months Ended March 31,								Nine Months Ended March 31,
	2024		2023		Increase				2024		2023		Increase (Decrease)
Homecare	$	12,287,000	$	10,971,000	$	1,316,000	12.0	%	$	36,108,000	$	31,335,000	$	4,773,000		15.2	%
Hospital		783,000		440,000		343,000	78.0	%		1,909,000		1,420,000		489,000		34.4	%
Homecare distributor		524,000		501,000		23,000	4.6	%		1,377,000		1,391,000		(14,000	)	(1.0	%)
Other		277,000		156,000		121,000	77.6	%		490,000		309,000		181,000		58.6	%
Total	$	13,871,000	$	12,068,000	$	1,803,000	14.9	%	$	39,884,000	$	34,455,000	$	5,429,000		15.8	%

Homecare revenue. Homecare revenue increased by $1,316,000, or 12.0%, for the three months ended March 31, 2024, compared to the same period in the prior year. For the nine months ended March 31, 2024, homecare revenue was $36,108,000, representing an increase of $4,773,000, or 15.2%, compared to the same period in the prior year. The increase in revenue was due to an increase in direct sales representatives, and efficiencies recognized within our reimbursement department as a result of recent investments made to streamline the claims process in the nine months ended March 31, 2024.

Hospital revenue. Hospital revenue was $783,000, an increase of $343,000, or 78.0%, for the three months ended March 31, 2024, compared to the same period in the prior year. For the nine months ended March 31, 2024, hospital revenue was $1,909,000, an increase of $489,000, or 34.4%, compared to the same period in the prior year. The increases were primarily due to an increase in sales representatives focused on the hospital market as well as increased capital and disposable demand.

Homecare distributor revenue. Homecare distributor revenue increased by $23,000, or 4.6%, for the three months ended March 31, 2024, compared to the same period in the prior year. For the nine months ended March 31, 2024, homecare distributor revenue was $1,377,000, a decrease of $14,000, or 1.0%, compared to the same period in the prior year. The change in Homecare distributor sales were primarily a result of the timing of distributor purchases that can cause significant fluctuations in reported revenue on a quarterly basis.

Other revenue. Other revenue was $277,000, an increase of $121,000, or 77.6%, for the three months ended March 31, 2024, compared to the same period in the prior year. For the nine months ended March 31, 2024, other revenue was $490,000, an increase of $181,000, or 58.6%, compared to the same period in the prior year. The increase in other revenue was primarily due to the timing of international distributor purchases and purchases by customers that do not fall within the other markets described above, which caused significant fluctuations in reported revenue on a quarterly basis.

Gross profit

Gross profit increased to $10,382,000, or 74.8% of net revenues, for the three months ended March 31, 2024, from $9,056,000, or 75.0% of net revenues, in the same period in the prior year. Gross profit increased to $30,425,000, or 76.3% of net revenues, for the nine months ended March 31, 2024, from $26,069,000, or 75.7% of net revenues, in the same period in the prior year. The decrease in gross profit as a percentage of net revenues compared to the same three-month period in the prior year was primarily due to costs associated with the wind down of our previous generator models. The increase in gross profit as a percentage of net revenues compared to the same nine-month period in the prior year was primarily due to decreased shipping expenses and increased material costs in the prior year to expedite inventory purchases which did not recur in the current year.

Operating expenses

Selling, general and administrative expenses. Selling, general and administrative (“SG&A”) expenses were $8,374,000 and $25,699,000 for the three and nine months ended March 31, 2024, respectively, representing increases of $680,000 and $2,762,000, or 8.8% and 12.0%, respectively, compared to the same periods in the prior year.

Payroll and compensation-related expenses were $5,721,000 and $17,111,000 for the three and nine months ended March 31, 2024, respectively, representing increases of $684,000 and $2,191,000, or 13.6% and 14.7%, respectively, compared to the same periods in the prior year. The increase in the current year periods were primarily due to increases in share-based compensation, salaries, and incentive compensation related to the higher average number of sales, sales support, marketing, and reimbursement personnel to process higher patient referrals. We have also continued to provide regular merit-based increases for our employees and are regularly benchmarking our compensation ranges including share-based compensation for new and existing employees to ensure we can hire and retain the talent needed to drive growth in our business. Field sales employees totaled 59 as of March 31, 2024, 51 of which were direct sales representatives, compared to 57 field sales employees and 48 direct sales representatives as of March 31, 2023.

Travel, meals and entertainment expenses were $760,000 and $2,453,000 for the three and nine months ended March 31, 2024, respectively, representing increases of $102,000 and $163,000, or 15.5% and 7.1%, respectively, compared to the same periods in the prior year. The increase in the current year periods were due to a higher average number of direct sales representatives, higher travel costs, an increased number of sales territories, and a mid-year sales meeting held in Q3 FY 2024.

Total discretionary marketing expenses were $304,000 and $1,095,000 for the three and nine months ended March 31, 2024, respectively, representing increases of $92,000 and $514,000, or 43.4% and 88.5%, respectively, compared to the same periods in the prior year. The increases were primarily due to an investment in market research, direct-to-consumer and direct-to-physician marketing.

Professional fees were $978,000 and $3,222,000 for the three and nine months ended March 31, 2024, respectively, representing decreases of $410,000 and $628,000, or 29.5% and 16.3%, respectively, compared to the same periods in the prior year. Professional fees are primarily for services related to legal costs, shareowner services and reporting requirements, information technology technical support and consulting fees. The decrease in the three months ended March 31, 2024, were primarily related to legal and consulting costs associated with the termination of the Public Health Emergency for COVID-19 and recruiting costs for multiple senior leadership positions that has not recurred in the fiscal year ending June 30, 2024 (“fiscal 2024”). In addition to those fees that did not recur in the third quarter, the decreases in the nine months ended March 31, 2024, were due to legal fees in fiscal 2023 related to a reimbursement project that has not recurred in fiscal 2024.

Research and development expenses. Research and development (“R&D”) expenses were $167,000 and $480,000 for the three and nine months ended March 31, 2024, respectively, representing an increase of $1,000, or 0.6%, and a decrease of $138,000, or 22.3%, respectively, compared to the same periods in the prior year. The decrease in the nine months ended March 31, 2024, were primarily due to reduced costs associated with our SmartVest Clearway platform development in the prior year which has now been launched into the Homecare and Hospital markets.

Interest income, net

Net interest income for the three and nine months ended March 31, 2024, was $120,000 and $293,000, respectively, compared to $26,000 and $37,000, respectively, for the same periods in the prior year. These increases were due to increased savings rates on higher cash balances.

Income tax expense

Income tax expense was estimated at $468,000 and $1,217,000, and the effective tax rate was 23.9% and 26.8%, for the three and nine months ended March 31, 2024, respectively. Estimated income tax expense for the three and nine months ended March 31, 2024, includes a discrete tax benefit of $99,000 and $95,000, respectively, primarily related to the exercise of stock options.

Income tax expense was estimated at $147,000 and $418,000, and the effective tax rate was 12.0% and 16.4%, for the three and nine months ended March 31, 2023, respectively. Estimated income tax expense for the three and nine months ended March 31, 2023, includes a discrete tax benefit of $176,000 and $219,000, respectively, related to the exercise of stock options.

Net income

Net income for the three and nine months ended March 31, 2024, was $1,493,000 and $3,322,000, respectively, compared to $1,075,000 and $2,133,000 for the same periods in the prior year. The increases in net income were driven primarily by net revenues growth and an increase in interest income.

Liquidity and Capital Resources

Cash Flows and Sources of Liquidity

Cash Flows provided by Operating Activities

For the nine months ended March 31, 2024, net cash provided by operating activities was $4,578,000. Cash flows provided by operating activities consisted of net income of $3,322,000, non-cash expenses of $1,920,000, a decrease in prepaid expenses and other assets of $1,234,000, an increase in income tax receivable, net, of $627,000, a decrease in accounts receivable of $223,000, and a decrease in inventory of $78,000. These cash flows from operating activities were offset by a decrease in accounts payable and accrued liabilities of $1,386,000, an increase in contract assets of $155,000, and a decrease in accrued compensation of $31,000.

The decrease in prepaid expenses and other assets, as well as the decrease in accounts payable and other accrued liabilities are primarily due to a litigation settlement payment related to our previously disclosed cyber security breach. The payment to the settlement fund during the first quarter of fiscal 2024 for the settlement amount of $825,000 was covered by insurance resulting in a reduction in other current assets and other accrued liabilities.

Cash Flows used in Investing Activities

For the nine months ended March 31, 2024, cash used in investing activities was $349,000. Cash used in investing activities consisted of $265,000 in expenditures for property and equipment and $84,000 in expenditures for intangible asset costs.

Cash Flows provided by Financing Activities

For the nine months ended March 31, 2024, cash provided by financing activities was $111,000, consisting of cash received for stock option exercises.

Adequacy of Capital Resources

Our primary working capital requirements relate to adding employees to our sales force and support functions, continuing infrastructure investments, and supporting general corporate needs, including financing equipment purchases and other capital expenditures incurred in the ordinary course of business. Based on our current operational performance, we believe our working capital of $34,996,000 and available borrowings under our existing credit facility will provide sufficient liquidity to meet our anticipated working capital and other liquidity needs for the next twelve months from the date of this report.

Our credit facility provides us with a revolving line of credit. Interest on borrowings on the line of credit accrues at the prime rate (8.50% on March 31, 2024) less 1.00% and is payable monthly. There was no outstanding principal balance on the line of credit as of March 31, 2024, or June 30, 2023. The amount eligible for borrowing on the line of credit is limited to the lesser of $2,500,000 or 57.00% of eligible accounts receivable, and the line of credit expires on December 17, 2025, if not renewed. As of March 31, 2024, the maximum $2,500,000 was available under the line of credit. Payment obligations under the line of credit are secured by a security interest in substantially all of our tangible and intangible assets.

The documents governing our line of credit contain certain financial and nonfinancial covenants that include a minimum tangible net worth of not less than $10,125,000 and restrictions on our ability to incur certain additional indebtedness or pay dividends.

Any failure to comply with these covenants in the future may result in an event of default, which if not cured or waived, could result in the lender accelerating the maturity of our indebtedness, preventing access to additional funds under the line of credit, requiring prepayment of outstanding indebtedness, or refusing to renew the line of credit. If the maturity of the indebtedness is accelerated or the line of credit is not renewed, sufficient cash resources to satisfy the debt obligations may not be available and we may not be able to continue operations as planned. If we are unable to repay such indebtedness, the lender could foreclose on these assets.

For the nine months ended March 31, 2024, and 2023, we spent $265,000 and $1,221,000, respectively, on property and equipment. We currently expect to finance planned equipment purchases with cash flows from operations or borrowings under our credit facility. We may need to incur additional debt if we have an unforeseen need for additional capital equipment or if our operating performance does not generate adequate cash flows.

While the impact of macroeconomic factors such as inflation are difficult to predict, we believe our cash, cash equivalents and cash flows from operations will be sufficient to meet our working capital, capital expenditure, operational cash requirements for fiscal 2024 and the foreseeable future. We will continue to evaluate our projected expenditures relative to our available cash and evaluate financing alternatives to satisfy our working capital and other cash requirements.

Information Regarding Forward-Looking Statements

Statements contained in this Quarterly Report on Form 10-Q that are not statements of historical fact should be considered forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward- looking statements include, but are not limited to, statements regarding: our business strategy, including our intended level of investment in R&D and marketing activities; our expectations with respect to earnings, gross margins and sales growth, industry relationships, marketing strategies and international sales; estimated sizes of markets into which our products are or may be sold; our business strengths and competitive advantages; our ability to grow additional sales distribution channels; our intent to retain any earnings for use in operations rather than paying dividends; our expectation that our products will continue to qualify for reimbursement and payment under government and private insurance programs; our intellectual property plans and practices; the expected impact of applicable regulations on our business; our beliefs about our manufacturing processes; our expectations and beliefs with respect to our employees and our relationships with them; our belief that our current facilities are adequate to support our growth plans; our expectations with respect to ongoing compliance with the terms of our credit facility; our expectations regarding the ongoing availability of credit and our ability to renew our line of credit; enhancements to our products and services; expected excise tax exemption for the SmartVest System; and our anticipated revenues, expenses, capital requirements and liquidity. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “project,” “goal,” “target,” “should,” “will,” “would,” and similar expressions, including the negative of these terms, are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Although we believe these forward-looking statements are reasonable, they involve risks and uncertainties that may cause actual results to differ materially from those projected by such statements. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results or our industry’s actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements.

Factors that could cause actual results to differ from those discussed in the forward-looking statements include, but are not limited to, the following:

●

ability to obtain reimbursement from Medicare, Medicaid, or private insurance payers for our products including potential adverse impact with an expiration of the Centers for Medicare and Medicaid Services waiver for certain respiratory diseases;

●

component or raw material shortages, changes to lead times or significant price increases;

●

adverse changes to state and federal health care regulations;

●

our ability to maintain regulatory compliance and to gain future regulatory approvals and clearances;

●

entry of new competitors including new drug or pharmaceutical discoveries;

●

adverse economic and business conditions or intense competition;

●

the risks associated with our planned salesforce expansion;

●

wage and component price inflation;

●

technical problems with our research and products;

●

the risks associated with cyberattacks, data breaches, computer viruses and other similar security threats;

●

changes affecting the medical device industry;

●

our ability to develop new sales channels for our products such as the homecare distributor channel;

●

adverse international health care regulation impacting current international business;

●

our ability to renew our line of credit or obtain additional credit as necessary; and

●

our ability to protect and expand our intellectual property portfolio.

This list of factors is not exhaustive, however, and these or other factors, many of which are outside of our control, could have a material adverse effect on us and our results of operations. Therefore, you should consider these risk factors with caution and form your own critical and independent conclusions about the likely effect of these risk factors on our future performance. Forward-looking statements speak only as of the date on which the statements are made, and we undertake no obligation, and expressly disclaim any such obligation, to update any forward-looking statement for any reason other than as required by law, even if new information becomes available or other events occur in the future. You should carefully review the disclosures and the risk factors described in this and other documents we file from time to time with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for fiscal 2023. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth herein.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item.

Item 4.

Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, as of the end of the period subject to this Quarterly Report on Form 10-Q. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the date of such evaluation to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms.

Changes to Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings.

Occasionally, we may be party to legal actions, proceedings, or claims in the ordinary course of business, including claims based on assertions of patent and trademark infringement. We are not party to any material pending legal proceedings.

Item 1A. Risk Factors.

As a smaller reporting company, we are not required to provide disclosure pursuant to this Item.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

On May 26, 2021, our Board of Directors (the “Board”) approved the repurchase of up to $3.0 million of outstanding shares of our common stock. The shares of our common stock may be repurchased under the authorization on the open market or in privately negotiated transactions subject to applicable securities laws and regulations. The current repurchase authorization does not expire and the approximate dollar value of shares that may yet be purchased under the plan as of March 31, 2024, was approximately $275,000. There were no share repurchases for the period covered by this Quarterly Report on Form 10-Q.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

None.

Item 5.

Other Information.

During the three months ended March 31, 2024, no director or officer of the Company adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

Item 6.

Exhibits.

Exhibit Number	Description	Method of Filing
3.1	Composite Articles of Incorporation, as amended through November 8, 2010 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K for the fiscal year ended June 30, 2015)	Incorporated by Reference

3.2	Amended and Restated Bylaws, effective September 29, 2020 (incorporated by reference to Exhibit 3.1 to Current Report on Form 8-K filed September 29, 2020)	Incorporated by Reference

31.1	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

31.2	Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Electronically

32.1	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished Electronically

32.2	Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished Electronically

101	Financial statements from the Quarterly Report on Form 10-Q for the period ended March 31, 2024, formatted in inline XBRL: (i) Condensed Balance Sheets, (ii) Condensed Statements of Operations, (iii) Condensed Statements of Cash Flows, (iv) Condensed Statements of Shareholders’ Equity, and (v) Notes to Condensed Financial Statements	Filed Electronically

104	Cover Page Interactive Data File (embedded within the inline XBRL Document)	Filed Electronically

* Management compensatory contract or arrangement

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		ELECTROMED, INC.

Date:	May 7, 2024	/s/ James L. Cunniff
		James L. Cunniff, President and Chief Executive Officer (duly authorized officer)

Date:	May 7, 2024	/s/ Bradley M. Nagel
		Bradley M. Nagel, Chief Financial Officer
		(principal financial officer and principal accounting officer)

EX-31.1 2 elmd240512_ex31-1.htm CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, James L. Cunniff, certify that:

I have reviewed this report on Form 10-Q of Electromed, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2024	/s/ James L. Cunniff
	James L. Cunniff
	President and Chief Executive Officer

EX-31.2 3 elmd240512_ex31-2.htm CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Bradley M. Nagel, certify that:

I have reviewed this report on Form 10-Q of Electromed, Inc.;

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2024	/s/ Bradley M. Nagel
	Bradley M. Nagel
	Chief Financial Officer

EX-32.1 4 elmd240512_ex32-1.htm CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Electromed, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, James L. Cunniff, President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2024	/s/ James L. Cunniff
	James L. Cunniff
	President and Chief Executive Officer

EX-32.2 5 elmd240512_ex32-2.htm CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Electromed, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024, as filed with the Securities and Exchange Commission (the “Report”), I, Bradley M. Nagel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 7, 2024	/s/ Bradley M. Nagel
	Bradley M. Nagel
	Chief Financial Officer

EX-101.CAL 6 elmd-20240331_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 elmd-20240331_def.xml XBRL DEFINITION FILE EX-101.LAB 8 elmd-20240331_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Product and Service [Axis] Home Care [Member] Hospital [Member] Home Care Distributor [Member] Other [Member] Payer Type [Axis] Commercial [Member] Medicare [Member] Medicare Supplemental [Member] Medicaid [Member] Other Homecare [Member] Lender Name [Axis] Revolving Credit Facility [Member] Variable Rate [Axis] Prime Rate [Member] Class of Stock [Axis] Capital Stock [Member] Authorized Shares Undesignated Stock [Member] Title of Individual [Axis] Board of Directors Chairman [Member] Award Type [Axis] Share-Based Payment Arrangement, Option [Member] Restricted Stock [Member] Plan Name [Axis] Employee [Member] Director [Member] Restricted Stock Units (RSUs) [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current Assets Cash and cash equivalents Accounts receivable (net of allowances for credit losses of $45,000) Contract assets Inventories Prepaid expenses and other current assets Income tax receivable Total current assets Property and equipment, net Finite-life intangible assets, net Other assets Deferred income taxes Total assets Liabilities and Shareholders' Equity Current Liabilities Accounts payable Accrued compensation Income tax payable Warranty reserve Other accrued liabilities Total current liabilities Other long-term liabilities Total liabilities Commitments and Contingencies Shareholders’ Equity Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,655,727 and 8,555,238 shares issued and outstanding, as of March 31, 2024, and June 30, 2023, respectively Additional paid-in capital Retained earnings Total shareholders' equity Total liabilities and shareholders' equity Accounts receivable, allowance for doubtful accounts Common stock, par value (in dollars per share) Common stock, authorized Common stock, outstanding Common stock, issued Income Statement [Abstract] Net revenues Cost of revenues Gross profit Operating expenses Selling, general and administrative Research and development Total operating expenses Operating income Interest income, net Net income before income taxes Income tax expense Net income Income per share: Basic Diluted Weighted-average common shares outstanding: Basic Diluted Statement of Cash Flows [Abstract] Cash Flows From Operating Activities Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation Amortization of finite-life intangible assets Share-based compensation expense Deferred income taxes Changes in operating assets and liabilities: Accounts receivable Contract assets Inventories Prepaid expenses and other assets Income tax receivable, net Accounts payable and accrued liabilities Accrued compensation Net cash provided by operating activities Cash Flows From Investing Activities Expenditures for property and equipment Expenditures for finite-life intangible assets Net cash used in investing activities Cash Flows From Financing Activities Issuance of common stock upon exercise of options Taxes paid on net share settlement of stock option exercises Repurchase of common stock Net cash provided by (used in) financing activities Net increase (decrease) in cash Cash and cash equivalents Beginning of period End of period Supplemental Disclosures of Cash Flow Information Cash paid for income taxes Supplemental Disclosures of Noncash Investing and Financing Activities Property and equipment acquisitions in accounts payable Intangible asset acquisitions in accounts payable Option exercise proceeds in other assets Demonstration equipment returned to inventory Statement [Table] Statement [Line Items] Balance on December 31, 2023 Balance at beginning (in shares) Issuance of restricted stock Issuance of restricted stock (in shares) Forfeiture of restricted stock Forfeiture of restricted stock (in shares) Issuance of common stock upon exercise of options Issuance of common stock upon exercise of options (in shares) EX-101.PRE 9 elmd-20240331_pre.xml XBRL PRESENTATION FILE EX-101.SCH 10 elmd-20240331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Interim Financial Reporting link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Revenues link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Warranty Reserve link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Financing Arrangements link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Interim Financial Reporting (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Revenues (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Warranty Reserve (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Interim Financial Reporting (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Schedule of disaggregated revenue (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Schedule of contract asset (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - The components of inventory were as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Changes in the Company’s warranty reserve were as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Income Taxes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Financing Arrangements (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details) link:presentationLink link:calculationLink link:definitionLink XML 12 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Mar. 31, 2024	May 02, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--06-30
Entity File Number	001-34839
Entity Registrant Name	Electromed, Inc.
Entity Central Index Key	0001488917
Entity Tax Identification Number	41-1732920
Entity Incorporation, State or Country Code	MN
Entity Address, Address Line One	500 Sixth Avenue NW
Entity Address, City or Town	New Prague
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	56071
City Area Code	(952)
Local Phone Number	758-9299
Title of 12(b) Security	Common Stock, $0.01 par value
Trading Symbol	ELMD
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,655,727

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Current Assets
Cash and cash equivalents	$ 11,712,000	$ 7,372,000
Accounts receivable (net of allowances for credit losses of $45,000)	23,907,000	24,130,000
Contract assets	642,000	487,000
Inventories	4,178,000	4,221,000
Prepaid expenses and other current assets	592,000	1,577,000
Income tax receivable	291,000
Total current assets	41,322,000	37,787,000
Property and equipment, net	5,283,000	5,672,000
Finite-life intangible assets, net	648,000	605,000
Other assets	106,000	161,000
Deferred income taxes	1,542,000	1,581,000
Total assets	48,901,000	45,806,000
Current Liabilities
Accounts payable	792,000	1,372,000
Accrued compensation	2,987,000	3,018,000
Income tax payable		336,000
Warranty reserve	1,525,000	1,378,000
Other accrued liabilities	1,022,000	1,949,000
Total current liabilities	6,326,000	8,053,000
Other long-term liabilities	31,000	86,000
Total liabilities	6,357,000	8,139,000
Shareholders’ Equity
Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,655,727 and 8,555,238 shares issued and outstanding, as of March 31, 2024, and June 30, 2023, respectively	87,000	86,000
Additional paid-in capital	20,342,000	18,788,000
Retained earnings	22,115,000	18,793,000
Total shareholders' equity	42,544,000	37,667,000
Total liabilities and shareholders' equity	$ 48,901,000	$ 45,806,000

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 45,000	$ 45,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized	13,000,000	13,000,000
Common stock, outstanding	8,655,727	8,555,238
Common stock, issued	8,655,727	8,555,238

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Net revenues	$ 13,871,000	$ 12,068,000	$ 39,884,000	$ 34,455,000
Cost of revenues	3,489,000	3,012,000	9,459,000	8,386,000
Gross profit	10,382,000	9,056,000	30,425,000	26,069,000
Operating expenses
Selling, general and administrative	8,374,000	7,694,000	25,699,000	22,937,000
Research and development	167,000	166,000	480,000	618,000
Total operating expenses	8,541,000	7,860,000	26,179,000	23,555,000
Operating income	1,841,000	1,196,000	4,246,000	2,514,000
Interest income, net	120,000	26,000	293,000	37,000
Net income before income taxes	1,961,000	1,222,000	4,539,000	2,551,000
Income tax expense	468,000	147,000	1,217,000	418,000
Net income	$ 1,493,000	$ 1,075,000	$ 3,322,000	$ 2,133,000
Income per share:
Basic	$ 0.17	$ 0.13	$ 0.39	$ 0.25
Diluted	$ 0.17	$ 0.12	$ 0.38	$ 0.25
Weighted-average common shares outstanding:
Basic	8,565,725	8,461,531	8,549,352	8,449,623
Diluted	8,892,821	8,710,106	8,822,938	8,694,407

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash Flows From Operating Activities
Net income	$ 3,322,000	$ 2,133,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	594,000	370,000
Amortization of finite-life intangible assets	37,000	52,000
Share-based compensation expense	1,250,000	506,000
Deferred income taxes	39,000	32,000
Changes in operating assets and liabilities:
Accounts receivable	223,000	(1,293,000)
Contract assets	(155,000)	(284,000)
Inventories	78,000	(264,000)
Prepaid expenses and other assets	1,234,000	105,000
Income tax receivable, net	(627,000)	(270,000)
Accounts payable and accrued liabilities	(1,386,000)	(111,000)
Accrued compensation	(31,000)	(660,000)
Net cash provided by operating activities	4,578,000	316,000
Cash Flows From Investing Activities
Expenditures for property and equipment	(265,000)	(1,221,000)
Expenditures for finite-life intangible assets	(84,000)	(54,000)
Net cash used in investing activities	(349,000)	(1,275,000)
Cash Flows From Financing Activities
Issuance of common stock upon exercise of options	111,000	40,000
Taxes paid on net share settlement of stock option exercises		(305,000)
Repurchase of common stock		(153,000)
Net cash provided by (used in) financing activities	111,000	(418,000)
Net increase (decrease) in cash	4,340,000	(1,377,000)
Cash and cash equivalents
Beginning of period	7,372,000	8,153,000
End of period	11,712,000	6,776,000
Supplemental Disclosures of Cash Flow Information
Cash paid for income taxes	1,806,000	655,000
Supplemental Disclosures of Noncash Investing and Financing Activities
Property and equipment acquisitions in accounts payable	35,000	136,000
Intangible asset acquisitions in accounts payable		6,000
Option exercise proceeds in other assets	194,000
Demonstration equipment returned to inventory	$ 35,000	$ 9,000

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance on December 31, 2023 at Jun. 30, 2022	$ 85,000	$ 18,308,000	$ 15,780,000	$ 34,173,000
Balance at beginning (in shares) at Jun. 30, 2022	8,475,438
Net income			81,000	81,000
Issuance of restricted stock
Issuance of restricted stock (in shares)	27,400
Forfeiture of restricted stock
Forfeiture of restricted stock (in shares)	(14,166)
Issuance of common stock upon exercise of options
Issuance of common stock upon exercise of options (in shares)	11,760
Taxes paid on stock options exercised on a net basis		(60,000)		(60,000)
Share-based compensation expense		95,000		95,000
Repurchase of common stock			(145,000)	(145,000)
Repurchase of common stock (in shares)	(14,568)
Balance on March 31, 2024 at Sep. 30, 2022	$ 85,000	18,343,000	15,716,000	34,144,000
Balance at ending (in shares) at Sep. 30, 2022	8,485,864
Balance on December 31, 2023 at Jun. 30, 2022	$ 85,000	18,308,000	15,780,000	34,173,000
Balance at beginning (in shares) at Jun. 30, 2022	8,475,438
Net income				2,133,000
Repurchase of common stock				(153,000)
Balance on March 31, 2024 at Mar. 31, 2023	$ 86,000	18,548,000	17,760,000	36,394,000
Balance at ending (in shares) at Mar. 31, 2023	8,556,600
Balance on December 31, 2023 at Sep. 30, 2022	$ 85,000	18,343,000	15,716,000	34,144,000
Balance at beginning (in shares) at Sep. 30, 2022	8,485,864
Net income			977,000	977,000
Issuance of restricted stock
Issuance of restricted stock (in shares)	26,000
Issuance of common stock upon exercise of options		16,000		16,000
Issuance of common stock upon exercise of options (in shares)	3,100
Share-based compensation expense		221,000		221,000
Repurchase of common stock			(8,000)	(8,000)
Repurchase of common stock (in shares)	(800)
Balance on March 31, 2024 at Dec. 31, 2022	$ 85,000	18,580,000	16,685,000	35,350,000
Balance at ending (in shares) at Dec. 31, 2022	8,514,164
Net income			1,075,000	1,075,000
Issuance of common stock upon exercise of options	1,000	23,000		$ 24,000
Issuance of common stock upon exercise of options (in shares)				42,436
Taxes paid on stock options exercised on a net basis		(245,000)		$ (245,000)
Share-based compensation expense		190,000		190,000
Balance on March 31, 2024 at Mar. 31, 2023	$ 86,000	18,548,000	17,760,000	36,394,000
Balance at ending (in shares) at Mar. 31, 2023	8,556,600
Balance on December 31, 2023 at Jun. 30, 2023	$ 86,000	18,788,000	18,793,000	$ 37,667,000
Balance at beginning (in shares) at Jun. 30, 2023	8,555,238			8,555,238
Net income			155,000	$ 155,000
Issuance of restricted stock
Issuance of restricted stock (in shares)	20,878
Issuance of common stock upon exercise of options		29,000		29,000
Issuance of common stock upon exercise of options (in shares)	2,934
Share-based compensation expense		371,000		371,000
Balance on March 31, 2024 at Sep. 30, 2023	$ 86,000	19,188,000	18,948,000	38,222,000
Balance at ending (in shares) at Sep. 30, 2023	8,579,050
Balance on December 31, 2023 at Jun. 30, 2023	$ 86,000	18,788,000	18,793,000	$ 37,667,000
Balance at beginning (in shares) at Jun. 30, 2023	8,555,238			8,555,238
Net income				$ 3,322,000
Repurchase of common stock
Repurchase of common stock (in shares)				(239,995)
Balance on March 31, 2024 at Mar. 31, 2024	$ 87,000	20,342,000	22,115,000	$ 42,544,000
Balance at ending (in shares) at Mar. 31, 2024	8,655,727			8,655,727
Balance on December 31, 2023 at Sep. 30, 2023	$ 86,000	19,188,000	18,948,000	$ 38,222,000
Balance at beginning (in shares) at Sep. 30, 2023	8,579,050
Net income			1,674,000	1,674,000
Issuance of restricted stock
Issuance of restricted stock (in shares)	21,000
Issuance of common stock upon exercise of options		26,000		26,000
Issuance of common stock upon exercise of options (in shares)	2,627
Share-based compensation expense		420,000		420,000
Balance on March 31, 2024 at Dec. 31, 2023	$ 86,000	19,634,000	20,622,000	40,342,000
Balance at ending (in shares) at Dec. 31, 2023	8,602,677
Net income			1,493,000	1,493,000
Issuance of restricted stock
Issuance of restricted stock (in shares)	2,550
Issuance of common stock upon exercise of options	$ 1,000	249,000		250,000
Issuance of common stock upon exercise of options (in shares)	50,500
Share-based compensation expense		459,000		459,000
Balance on March 31, 2024 at Mar. 31, 2024	$ 87,000	$ 20,342,000	$ 22,115,000	$ 42,544,000
Balance at ending (in shares) at Mar. 31, 2024	8,655,727			8,655,727

XML 18 R7.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting

9 Months Ended

Mar. 31, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Interim Financial Reporting

Note 1. Interim Financial Reporting

Since its inception, the Company has operated in a single industry segment: developing, manufacturing, and marketing medical equipment.

A summary of the Company’s significant accounting policies follows:

Recently Issued Accounting Standards

XML 19 R8.htm IDEA: XBRL DOCUMENT

Revenues

9 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Revenues

Note 2. Revenues

Disaggregation of revenues. In the following table, net revenues are disaggregated by market:

Schedule of disaggregated revenue

	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Homecare	$	12,287,000	$	10,971,000	$	36,108,000	$	31,335,000
Hospital		783,000		440,000		1,909,000		1,420,000
Homecare distributor		524,000		501,000		1,377,000		1,391,000
Other		277,000		156,000		490,000		309,000
Total	$	13,871,000	$	12,068,000	$	39,884,000	$	34,455,000

In the following table, net homecare revenue is disaggregated by payer type:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Commercial	$	5,974,000	$	4,787,000	$	17,684,000	$	12,706,000
Medicare		4,825,000		4,544,000		13,666,000		13,753,000
Medicare Supplemental		1,177,000		1,278,000		3,447,000		3,681,000
Medicaid		115,000		128,000		722,000		618,000
Other homecare		196,000		234,000		589,000		577,000
Total	$	12,287,000	$	10,971,000	$	36,108,000	$	31,335,000

Revenues are recognized at a point in time when control passes to the customer upon product shipment or delivery.

●

Contract balances. The following table provides information about contract assets from contracts with customers:

Schedule of contract asset

	Nine Months Ended March 31, 2024			Fiscal Year Ended June 30, 2023
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	487,000		$	286,000
Reclassification of contract assets to accounts receivable		(1,453,000	)		(1,220,000	)
Contract assets recognized		1,829,000			1,351,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(221,000	)		70,000
Contract assets, ending	$	642,000		$	487,000

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

XML 20 R9.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

Inventories

Note 3. Inventories

The components of inventory were as follows:

	March 31, 2024			June 30, 2023
Parts inventory	$	3,016,000		$	3,420,000
Work in process		449,000			470,000
Finished goods		856,000			323,000
Estimated inventory to be returned		260,000			265,000
Less: Reserve for obsolescence		(403,000	)		(257,000	)
Total	$	4,178,000		$	4,221,000

XML 21 R10.htm IDEA: XBRL DOCUMENT

Warranty Reserve

9 Months Ended

Mar. 31, 2024

Guarantees and Product Warranties [Abstract]

Warranty Reserve

Note 4. Warranty Reserve

Changes in the Company’s warranty reserve were as follows:

	Nine Months Ended March 31, 2024			Fiscal Year Ended June 30, 2023
Warranty reserve, beginning	$	1,378,000		$	1,256,000
Accrual for products sold		426,000			416,000
Expenditures and costs incurred for warranty claims		(279,000	)		(294,000	)
Warranty reserve, ending	$	1,525,000		$	1,378,000

XML 22 R11.htm IDEA: XBRL DOCUMENT

Income Taxes

9 Months Ended

Mar. 31, 2024

Income Tax Disclosure [Abstract]

Income Taxes

Note 5. Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Financing Arrangements

9 Months Ended

Mar. 31, 2024

Debt Disclosure [Abstract]

Financing Arrangements

Note 6. Financing Arrangements

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended

Mar. 31, 2024

Common Stock

Common Stock

Note 7. Common Stock

XML 25 R14.htm IDEA: XBRL DOCUMENT

Share-Based Compensation

9 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Compensation

Note 8. Share-Based Compensation

Stock Options

Stock option transactions during the nine months ended March 31, 2024, are summarized as follows:

	Number of Shares			Weighted-Average Exercise Price per Share
Outstanding on June 30, 2023		451,570		$	6.93
Granted		263,162		$	10.70
Exercised		(56,063	)	$	5.45
Cancelled or Forfeited		(21,079	)	$	10.46
Outstanding on March 31, 2024		637,590		$	8.50

The following assumptions were used to estimate the fair value of stock options granted:

	Nine Months Ended March 31, 2024	Fiscal Year Ended June 30, 2023
Risk-free interest rate	3.85 – 4.64%	2.88 - 4.23%
Expected term (years)	6	6
Expected volatility	51 - 53%	53% - 54%

Restricted Stock

Performance-Based Restricted Stock Units

XML 26 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Mar. 31, 2024

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

Note 9. Commitments and Contingencies

XML 27 R16.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting (Policies)	9 Months Ended
Interim Financial Reporting (Policies)	Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Use of estimates	Use of estimates. Management uses estimates and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation and warranty reserve.
Net income per common share	Net income per common share. Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were 289,362 and 179,992 for the three months ended March 31, 2024, and 2023, respectively, and were 400,639 and 200,140 for the nine months ended March 31, 2024, and 2023, respectively.
Recently Issued Accounting Standards	Recently Issued Accounting Standards In June 2016, the Financial Accounting Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments -- Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. The company adopted the standard effective July 1, 2023. The Company’s adoption of the standard did not have a material impact on the financial statements.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Revenues (Tables)

9 Months Ended

Mar. 31, 2024

Revenue from Contract with Customer [Abstract]

Schedule of disaggregated revenue

Disaggregation of revenues. In the following table, net revenues are disaggregated by market:

Schedule of disaggregated revenue

	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Homecare	$	12,287,000	$	10,971,000	$	36,108,000	$	31,335,000
Hospital		783,000		440,000		1,909,000		1,420,000
Homecare distributor		524,000		501,000		1,377,000		1,391,000
Other		277,000		156,000		490,000		309,000
Total	$	13,871,000	$	12,068,000	$	39,884,000	$	34,455,000

In the following table, net homecare revenue is disaggregated by payer type:

	Three Months Ended March 31,				Nine Months Ended March 31,
	2024		2023		2024		2023
Commercial	$	5,974,000	$	4,787,000	$	17,684,000	$	12,706,000
Medicare		4,825,000		4,544,000		13,666,000		13,753,000
Medicare Supplemental		1,177,000		1,278,000		3,447,000		3,681,000
Medicaid		115,000		128,000		722,000		618,000
Other homecare		196,000		234,000		589,000		577,000
Total	$	12,287,000	$	10,971,000	$	36,108,000	$	31,335,000

Schedule of contract asset

Contract balances. The following table provides information about contract assets from contracts with customers:

Schedule of contract asset

	Nine Months Ended March 31, 2024			Fiscal Year Ended June 30, 2023
	Increase (decrease)			Increase (decrease)
Contract assets, beginning	$	487,000		$	286,000
Reclassification of contract assets to accounts receivable		(1,453,000	)		(1,220,000	)
Contract assets recognized		1,829,000			1,351,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period		(221,000	)		70,000
Contract assets, ending	$	642,000		$	487,000

XML 29 R18.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Mar. 31, 2024

Inventory Disclosure [Abstract]

The components of inventory were as follows:

	March 31, 2024			June 30, 2023
Parts inventory	$	3,016,000		$	3,420,000
Work in process		449,000			470,000
Finished goods		856,000			323,000
Estimated inventory to be returned		260,000			265,000
Less: Reserve for obsolescence		(403,000	)		(257,000	)
Total	$	4,178,000		$	4,221,000

XML 30 R19.htm IDEA: XBRL DOCUMENT

Warranty Reserve (Tables)

9 Months Ended

Mar. 31, 2024

Guarantees and Product Warranties [Abstract]

Changes in the Company’s warranty reserve were as follows:

	Nine Months Ended March 31, 2024			Fiscal Year Ended June 30, 2023
Warranty reserve, beginning	$	1,378,000		$	1,256,000
Accrual for products sold		426,000			416,000
Expenditures and costs incurred for warranty claims		(279,000	)		(294,000	)
Warranty reserve, ending	$	1,525,000		$	1,378,000

XML 31 R20.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2024

Share-Based Payment Arrangement [Abstract]

Stock option transactions during the nine months ended March 31, 2024, are summarized as follows:

	Number of Shares			Weighted-Average Exercise Price per Share
Outstanding on June 30, 2023		451,570		$	6.93
Granted		263,162		$	10.70
Exercised		(56,063	)	$	5.45
Cancelled or Forfeited		(21,079	)	$	10.46
Outstanding on March 31, 2024		637,590		$	8.50

The following assumptions were used to estimate the fair value of stock options granted:

	Nine Months Ended March 31, 2024	Fiscal Year Ended June 30, 2023
Risk-free interest rate	3.85 – 4.64%	2.88 - 4.23%
Expected term (years)	6	6
Expected volatility	51 - 53%	53% - 54%

XML 32 R21.htm IDEA: XBRL DOCUMENT

Interim Financial Reporting (Details Narrative) - shares	3 Months Ended		9 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Common stock equivalents included from calculation of diluted earnings per share	289,362	179,992	400,639	200,140

XML 33 R22.htm IDEA: XBRL DOCUMENT

Schedule of disaggregated revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
Schedule of disaggregated revenue (Details) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 13,871,000	$ 12,068,000	$ 39,884,000	$ 34,455,000
Home Care [Member]
Disaggregation of Revenue [Line Items]
Revenue	12,287,000	10,971,000	36,108,000	31,335,000
Home Care [Member] \| Commercial [Member]
Disaggregation of Revenue [Line Items]
Revenue	5,974,000	4,787,000	17,684,000	12,706,000
Home Care [Member] \| Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue	4,825,000	4,544,000	13,666,000	13,753,000
Home Care [Member] \| Medicare Supplemental [Member]
Disaggregation of Revenue [Line Items]
Revenue	1,177,000	1,278,000	3,447,000	3,681,000
Home Care [Member] \| Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue	115,000	128,000	722,000	618,000
Home Care [Member] \| Other Homecare [Member]
Disaggregation of Revenue [Line Items]
Revenue	196,000	234,000	589,000	577,000
Hospital [Member]
Disaggregation of Revenue [Line Items]
Revenue	783,000	440,000	1,909,000	1,420,000
Home Care Distributor [Member]
Disaggregation of Revenue [Line Items]
Revenue	524,000	501,000	1,377,000	1,391,000
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue	$ 277,000	$ 156,000	$ 490,000	$ 309,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Schedule of contract asset (Details) - USD ($)	9 Months Ended	12 Months Ended
Schedule of contract asset (Details) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Revenue from Contract with Customer [Abstract]
Contract assets beginning	$ 487,000	$ 487,000
Reclassification of contract assets to accounts receivable	(1,453,000)	(1,220,000)
Contract assets recognized	1,829,000	1,351,000
Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period	(221,000)	70,000
Contract assets, ending	$ 642,000	$ 487,000

XML 35 R24.htm IDEA: XBRL DOCUMENT

The components of inventory were as follows: (Details) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Inventory Disclosure [Abstract]
Parts inventory	$ 3,016,000	$ 3,420,000
Work in process	449,000	470,000
Finished goods	856,000	323,000
Estimated inventory to be returned	260,000	265,000
Less: Reserve for obsolescence	(403,000)	(257,000)
Total	$ 4,178,000	$ 4,221,000

XML 36 R25.htm IDEA: XBRL DOCUMENT

Changes in the Company’s warranty reserve were as follows: (Details) - USD ($)	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Guarantees and Product Warranties [Abstract]
Warranty reserve, beginning	$ 1,378,000	$ 1,256,000
Accrual for products sold	426,000	416,000
Expenditures and costs incurred for warranty claims	(279,000)	(294,000)
Warranty reserve, ending	$ 1,525,000	$ 1,378,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Income Taxes (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2024	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income tax expense	$ 468,000	$ 147,000	$ 1,217,000	$ 418,000
Effective tax rate	23.90%	12.00%	26.80%	16.40%
Current income tax expense	$ 99,000	$ 176,000	$ 95,000	$ 219,000

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 38 R27.htm IDEA: XBRL DOCUMENT

Financing Arrangements (Details Narrative) - USD ($)	9 Months Ended
Financing Arrangements (Details Narrative) - USD ($)	Mar. 31, 2024	Jun. 30, 2023
Line of Credit Facility [Line Items]
Minimum tangible net worth to be maintained	$ 10,125,000
Revolving Credit Facility [Member]
Line of Credit Facility [Line Items]
Maximum borrowing capacity	2,500,000
Line of credit balance	$ 0	$ 0
Basis spread on rate	1.00%
Available borrowing capacity	$ 2,500,000
Borrowing capacity of eligible accounts receivable percent	57.00%
Available borrowing capacity	$ 2,500,000
Revolving Credit Facility [Member] \| Prime Rate [Member]
Line of Credit Facility [Line Items]
Interest rate	8.50%

XML 39 R28.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Common Stock (Details Narrative) - USD ($)	Dec. 31, 2022	Sep. 30, 2022	Mar. 31, 2024	Jun. 30, 2023	May 26, 2022
Common stock, authorized			13,000,000	13,000,000
Common stock, par value (in dollars per share)			$ 0.01	$ 0.01
Number of share repurchased			239,995
Repurchase of common stock			$ 2,725,000
Share price			$ 11.36
Board of Directors Chairman [Member]
Common stock, authorized					3,000,000
Common Stock [Member]
Common stock, authorized			13,000,000
Common stock, par value (in dollars per share)			$ 0.01
Number of share repurchased	800	14,568
Capital Stock [Member]
Common stock, authorized			15,000,000
Authorized Shares Undesignated Stock [Member]
Common stock, authorized			2,000,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: (Details) - $ / shares	3 Months Ended	9 Months Ended
	Mar. 31, 2023	Mar. 31, 2024
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercised	(42,436)
Option outstanding, ending		637,590
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option outstanding , beginning		451,570
Weighted average grant date fair value, beginning		$ 6.93
Granted		263,162
Granted		$ 10.70
Exercised		(56,063)
Exercised		$ 5.45
Cancelled or Forfeited		(21,079)
Cancelled or Forfeited		$ 10.46
Option outstanding, ending		637,590
Weighted average grant date fair value, ending		$ 8.50

XML 41 R30.htm IDEA: XBRL DOCUMENT

The following assumptions were used to estimate the fair value of stock options granted: (Details)	9 Months Ended	12 Months Ended
	Mar. 31, 2024	Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]
Risk free interest rate - minimum	3.85%	2.88%
Risk free interest rate - maximum	4.64%	4.23%
Expected term (years)	6 years	6 years
Expected volatility - maximum	51.00%	53.00%
Expected volatility - maximum	53.00%	54.00%

XML 42 R31.htm IDEA: XBRL DOCUMENT

Share-Based Compensation (Details Narrative) - USD ($)	9 Months Ended
Share-Based Compensation (Details Narrative) - USD ($)	Mar. 31, 2024	Mar. 31, 2023	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation expense	$ 1,250,000	$ 506,000
Shares outstanding	637,590
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	6 years 8 months 12 days
Options exercisable, intrinsic value	$ 4,878,000
Shares outstanding	637,590		451,570
Vested and exercisable	319,088
Options exercisable, intrinsic value	$ 3,118,000
Unrecognized compensation expense	$ 925,000
Unrecognized compensation expense, period for recognition	2 years 9 months 18 days
Shares granted	263,162
Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized compensation expense, period for recognition	1 year 4 months 24 days
Unrecognized compensation expense	$ 253,000
Restricted stock - unvested	57,661
Weight average fair value - unvested restricted stock (per share)	$ 10.53
Restricted Stock [Member] \| Director [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued	21,000
Fair value of per share	$ 10.44
Restricted Stock [Member] \| Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock issued	23,428
Vesting term	3 years
Fair value of per share	$ 10.74
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-based compensation expense	$ 217,000	$ 0
Unrecognized compensation expense, period for recognition	3 years 2 months 30 days
Shares outstanding	175,000
Unrecognized compensation expense	$ 935,000
Fair value of per share	$ 6.58
Shares granted	175,000
Other description	The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. The grant date fair value of the awards was determined using a Monte Carlo valuation model with an expected term of four years.

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 47 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 113 175 1 false 22 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://electromed.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://electromed.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://electromed.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://electromed.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://electromed.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Statements of Shareholders' Equity (Unaudited) Sheet http://electromed.com/role/StatementsOfShareholdersEquity Condensed Statements of Shareholders' Equity (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Interim Financial Reporting Sheet http://electromed.com/role/InterimFinancialReporting Interim Financial Reporting Notes 7 false false R8.htm 00000008 - Disclosure - Revenues Sheet http://electromed.com/role/Revenues Revenues Notes 8 false false R9.htm 00000009 - Disclosure - Inventories Sheet http://electromed.com/role/Inventories Inventories Notes 9 false false R10.htm 00000010 - Disclosure - Warranty Reserve Sheet http://electromed.com/role/WarrantyReserve Warranty Reserve Notes 10 false false R11.htm 00000011 - Disclosure - Income Taxes Sheet http://electromed.com/role/IncomeTaxes Income Taxes Notes 11 false false R12.htm 00000012 - Disclosure - Financing Arrangements Sheet http://electromed.com/role/FinancingArrangements Financing Arrangements Notes 12 false false R13.htm 00000013 - Disclosure - Common Stock Sheet http://electromed.com/role/CommonStock Common Stock Notes 13 false false R14.htm 00000014 - Disclosure - Share-Based Compensation Sheet http://electromed.com/role/Share-basedCompensation Share-Based Compensation Notes 14 false false R15.htm 00000015 - Disclosure - Commitments and Contingencies Sheet http://electromed.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 00000016 - Disclosure - Interim Financial Reporting (Policies) Sheet http://electromed.com/role/InterimFinancialReportingPolicies Interim Financial Reporting (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - Revenues (Tables) Sheet http://electromed.com/role/RevenuesTables Revenues (Tables) Tables http://electromed.com/role/Revenues 17 false false R18.htm 00000018 - Disclosure - Inventories (Tables) Sheet http://electromed.com/role/InventoriesTables Inventories (Tables) Tables http://electromed.com/role/Inventories 18 false false R19.htm 00000019 - Disclosure - Warranty Reserve (Tables) Sheet http://electromed.com/role/WarrantyReserveTables Warranty Reserve (Tables) Tables http://electromed.com/role/WarrantyReserve 19 false false R20.htm 00000020 - Disclosure - Share-Based Compensation (Tables) Sheet http://electromed.com/role/Share-basedCompensationTables Share-Based Compensation (Tables) Tables http://electromed.com/role/Share-basedCompensation 20 false false R21.htm 00000021 - Disclosure - Interim Financial Reporting (Details Narrative) Sheet http://electromed.com/role/InterimFinancialReportingDetailsNarrative Interim Financial Reporting (Details Narrative) Details http://electromed.com/role/InterimFinancialReportingPolicies 21 false false R22.htm 00000022 - Disclosure - Schedule of disaggregated revenue (Details) Sheet http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails Schedule of disaggregated revenue (Details) Details 22 false false R23.htm 00000023 - Disclosure - Schedule of contract asset (Details) Sheet http://electromed.com/role/ScheduleOfContractAssetDetails Schedule of contract asset (Details) Details 23 false false R24.htm 00000024 - Disclosure - The components of inventory were as follows: (Details) Sheet http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails The components of inventory were as follows: (Details) Details 24 false false R25.htm 00000025 - Disclosure - Changes in the Company???s warranty reserve were as follows: (Details) Sheet http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails Changes in the Company???s warranty reserve were as follows: (Details) Details 25 false false R26.htm 00000026 - Disclosure - Income Taxes (Details Narrative) Sheet http://electromed.com/role/IncomeTaxesDetailsNarrative Income Taxes (Details Narrative) Details http://electromed.com/role/IncomeTaxes 26 false false R27.htm 00000027 - Disclosure - Financing Arrangements (Details Narrative) Sheet http://electromed.com/role/FinancingArrangementsDetailsNarrative Financing Arrangements (Details Narrative) Details http://electromed.com/role/FinancingArrangements 27 false false R28.htm 00000028 - Disclosure - Common Stock (Details Narrative) Sheet http://electromed.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://electromed.com/role/CommonStock 28 false false R29.htm 00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: (Details) Sheet http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: (Details) Details 29 false false R30.htm 00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details) Sheet http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails The following assumptions were used to estimate the fair value of stock options granted: (Details) Details 30 false false R31.htm 00000031 - Disclosure - Share-Based Compensation (Details Narrative) Sheet http://electromed.com/role/Share-basedCompensationDetailsNarrative Share-Based Compensation (Details Narrative) Details http://electromed.com/role/Share-basedCompensationTables 31 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 14 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:CommonStockSharesAuthorized, us-gaap:ContractWithCustomerAssetNetCurrent, us-gaap:IncomeTaxExpenseBenefit, us-gaap:LinesOfCreditCurrent, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1, us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 - elmd240512_10q.htm 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116 elmd-20240331.xsd elmd-20240331_cal.xml elmd-20240331_def.xml elmd-20240331_lab.xml elmd-20240331_pre.xml elmd240512_10q.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 50 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "elmd240512_10q.htm": { "nsprefix": "elmd", "nsuri": "http://electromed.com/20240331", "dts": { "schema": { "local": [ "elmd-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "calculationLink": { "local": [ "elmd-20240331_cal.xml" ] }, "definitionLink": { "local": [ "elmd-20240331_def.xml" ] }, "labelLink": { "local": [ "elmd-20240331_lab.xml" ] }, "presentationLink": { "local": [ "elmd-20240331_pre.xml" ] }, "inline": { "local": [ "elmd240512_10q.htm" ] } }, "keyStandard": 165, "keyCustom": 10, "axisStandard": 8, "axisCustom": 1, "memberStandard": 10, "memberCustom": 12, "hidden": { "total": 93, "http://fasb.org/us-gaap/2023": 86, "http://electromed.com/20240331": 2, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 113, "entityCount": 1, "segmentCount": 22, "elementCount": 283, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 496, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://electromed.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://electromed.com/role/BalanceSheets", "longName": "00000002 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R3": { "role": "http://electromed.com/role/BalanceSheetsParenthetical", "longName": "00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://electromed.com/role/StatementsOfOperations", "longName": "00000004 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:Revenues", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R5": { "role": "http://electromed.com/role/StatementsOfCashFlows", "longName": "00000005 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:Depreciation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } }, "R6": { "role": "http://electromed.com/role/StatementsOfShareholdersEquity", "longName": "00000006 - Statement - Condensed Statements of Shareholders' Equity (Unaudited)", "shortName": "Condensed Statements of Shareholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "AsOf2022-06-30_us-gaap_CommonStockMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2022-07-012022-09-30_us-gaap_RetainedEarningsMember", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } }, "R7": { "role": "http://electromed.com/role/InterimFinancialReporting", "longName": "00000007 - Disclosure - Interim Financial Reporting", "shortName": "Interim Financial Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://electromed.com/role/Revenues", "longName": "00000008 - Disclosure - Revenues", "shortName": "Revenues", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://electromed.com/role/Inventories", "longName": "00000009 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://electromed.com/role/WarrantyReserve", "longName": "00000010 - Disclosure - Warranty Reserve", "shortName": "Warranty Reserve", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://electromed.com/role/IncomeTaxes", "longName": "00000011 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://electromed.com/role/FinancingArrangements", "longName": "00000012 - Disclosure - Financing Arrangements", "shortName": "Financing Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://electromed.com/role/CommonStock", "longName": "00000013 - Disclosure - Common Stock", "shortName": "Common Stock", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "elmd:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "elmd:CommonStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://electromed.com/role/Share-basedCompensation", "longName": "00000014 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://electromed.com/role/CommitmentsAndContingencies", "longName": "00000015 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://electromed.com/role/InterimFinancialReportingPolicies", "longName": "00000016 - Disclosure - Interim Financial Reporting (Policies)", "shortName": "Interim Financial Reporting (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:UseOfEstimates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://electromed.com/role/RevenuesTables", "longName": "00000017 - Disclosure - Revenues (Tables)", "shortName": "Revenues (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://electromed.com/role/InventoriesTables", "longName": "00000018 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://electromed.com/role/WarrantyReserveTables", "longName": "00000019 - Disclosure - Warranty Reserve (Tables)", "shortName": "Warranty Reserve (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://electromed.com/role/Share-basedCompensationTables", "longName": "00000020 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "20", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://electromed.com/role/InterimFinancialReportingDetailsNarrative", "longName": "00000021 - Disclosure - Interim Financial Reporting (Details Narrative)", "shortName": "Interim Financial Reporting (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails", "longName": "00000022 - Disclosure - Schedule of disaggregated revenue (Details)", "shortName": "Schedule of disaggregated revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:DisaggregationOfRevenueTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://electromed.com/role/ScheduleOfContractAssetDetails", "longName": "00000023 - Disclosure - Schedule of contract asset (Details)", "shortName": "Schedule of contract asset (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "23", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ContractWithCustomerAssetReclassifiedToReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ContractWithCustomerAssetReclassifiedToReceivable", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails", "longName": "00000024 - Disclosure - The components of inventory were as follows: (Details)", "shortName": "The components of inventory were as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "24", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OtherInventorySupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:OtherInventorySupplies", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "us-gaap:InventoryDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails", "longName": "00000025 - Disclosure - Changes in the Company\u2019s warranty reserve were as follows: (Details)", "shortName": "Changes in the Company\u2019s warranty reserve were as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "25", "firstAnchor": { "contextRef": "AsOf2023-06-30", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2022-06-30", "name": "us-gaap:ProductWarrantyAccrual", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "us-gaap:ProductWarrantyDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } }, "R26": { "role": "http://electromed.com/role/IncomeTaxesDetailsNarrative", "longName": "00000026 - Disclosure - Income Taxes (Details Narrative)", "shortName": "Income Taxes (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "26", "firstAnchor": { "contextRef": "From2023-01-012023-03-31", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2024-01-012024-03-31", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } }, "R27": { "role": "http://electromed.com/role/FinancingArrangementsDetailsNarrative", "longName": "00000027 - Disclosure - Financing Arrangements (Details Narrative)", "shortName": "Financing Arrangements (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "elmd:DebtInstrumentCovenantComplianceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31", "name": "elmd:DebtInstrumentCovenantComplianceAmount", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://electromed.com/role/CommonStockDetailsNarrative", "longName": "00000028 - Disclosure - Common Stock (Details Narrative)", "shortName": "Common Stock (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "AsOf2024-03-31", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:StockRepurchasedAndRetiredDuringPeriodValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "elmd:CommonStockTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } }, "R29": { "role": "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails", "longName": "00000029 - Disclosure - Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: (Details)", "shortName": "Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "From2023-01-012023-03-31", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2023-06-30_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "unitRef": "USDPShares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } }, "R30": { "role": "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails", "longName": "00000030 - Disclosure - The following assumptions were used to estimate the fair value of stock options granted: (Details)", "shortName": "The following assumptions were used to estimate the fair value of stock options granted: (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "unitRef": "Pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "longName": "00000031 - Disclosure - Share-Based Compensation (Details Narrative)", "shortName": "Share-Based Compensation (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "From2023-07-01to2024-03-31", "name": "us-gaap:ShareBasedCompensation", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "AsOf2024-03-31_us-gaap_EmployeeStockOptionMember", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "elmd240512_10q.htm", "unique": true } } }, "tag": { "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r11", "r412" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts receivable (net of allowances for credit losses of $45,000)", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r156", "r157" ] }, "elmd_AccruedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "AccruedCompensation", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued compensation", "documentation": "This element represent accrued compensation.", "label": "Accrued Compensation" } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r43", "r75" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r46", "r412", "r505" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r253", "r254", "r255", "r329", "r457", "r458", "r459", "r496", "r506" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Share-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r34", "r35", "r221" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://electromed.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Accounts receivable, allowance for doubtful accounts", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r99", "r158", "r162" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of finite-life intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r4", "r28", "r29" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r438" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://electromed.com/role/InterimFinancialReportingDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock equivalents included from calculation of diluted earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r136" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r73", "r95", "r113", "r141", "r147", "r151", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r275", "r277", "r288", "r301", "r361", "r412", "r423", "r466", "r467", "r499" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r91", "r101", "r113", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r275", "r277", "r288", "r412", "r466", "r467", "r499" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsDesignatedToClosedBlockIncomeTaxReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsDesignatedToClosedBlockIncomeTaxReceivable", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Income tax receivable", "documentation": "Amount of tax refunds receivable held by the closed block." } } }, "auth_ref": [ "r38", "r39" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r438" ] }, "elmd_AuthorizedSharesUndesignatedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "AuthorizedSharesUndesignatedStockMember", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Authorized Shares Undesignated Stock [Member]", "documentation": "This member stands for authorized shares undesignated stock member." } } }, "auth_ref": [] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Board of Directors Chairman [Member]" } } }, "auth_ref": [ "r461" ] }, "elmd_BorrowingCapacityOfEligibleAccountsReceivablePercent": { "xbrltype": "percentItemType", "nsuri": "http://electromed.com/20240331", "localname": "BorrowingCapacityOfEligibleAccountsReceivablePercent", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Borrowing capacity of eligible accounts receivable percent", "documentation": "This element represent borrowing capacity of eligible accounts receivable percent." } } }, "auth_ref": [] }, "elmd_CapitalStockMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "CapitalStockMember", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Capital Stock [Member]", "documentation": "This member stands for capital stock member." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r20", "r93", "r397" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning of period", "periodEndLabel": "End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r20", "r60", "r111" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r60" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Noncash Investing and Financing Activities" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r88", "r96", "r97", "r98", "r113", "r130", "r131", "r133", "r135", "r139", "r140", "r159", "r178", "r180", "r181", "r182", "r185", "r186", "r198", "r199", "r200", "r201", "r202", "r288", "r323", "r324", "r325", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r349", "r370", "r387", "r390", "r391", "r392", "r393", "r394", "r444", "r453", "r460" ] }, "elmd_CommercialMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "CommercialMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Commercial [Member]", "documentation": "This member stands for commercial member." } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r16", "r37", "r302", "r348" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://electromed.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r67", "r164", "r165", "r395", "r463" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r457", "r458", "r496", "r503", "r506" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://electromed.com/role/BalanceSheetsParenthetical", "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://electromed.com/role/BalanceSheetsParenthetical", "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Common stock, authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r45", "r349" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://electromed.com/role/BalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common stock, issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://electromed.com/role/BalanceSheetsParenthetical", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock, outstanding", "periodStartLabel": "Balance at beginning (in shares)", "periodEndLabel": "Balance at ending (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r6", "r45", "r349", "r367", "r506", "r507" ] }, "elmd_CommonStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://electromed.com/20240331", "localname": "CommonStockTextBlock", "presentation": [ "http://electromed.com/role/CommonStock" ], "lang": { "en-us": { "role": { "verboseLabel": "Common Stock", "documentation": "This member stands for common stock text block.", "label": "Common Stock [Text Block]" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, $0.01 par value per share, 13,000,000 shares authorized; 8,655,727 and 8,555,238 shares issued and outstanding, as of March 31, 2024, and June 30, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r45", "r303", "r412" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://electromed.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of contract asset", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r468" ] }, "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": [ "http://electromed.com/role/ScheduleOfContractAssetDetails" ], "lang": { "en-us": { "role": { "label": "Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": [ "r402" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets", "http://electromed.com/role/ScheduleOfContractAssetDetails" ], "lang": { "en-us": { "role": { "label": "Contract assets", "periodStartLabel": "Contract assets beginning", "periodEndLabel": "Contract assets, ending", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r204", "r205", "r216" ] }, "us-gaap_ContractWithCustomerAssetReclassifiedToReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetReclassifiedToReceivable", "crdr": "credit", "presentation": [ "http://electromed.com/role/ScheduleOfContractAssetDetails" ], "lang": { "en-us": { "role": { "label": "Reclassification of contract assets to accounts receivable", "documentation": "Amount of decrease in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time from transfer to receivable due to right to consideration becoming unconditional." } } }, "auth_ref": [ "r403" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://electromed.com/role/ScheduleOfContractAssetDetails" ], "lang": { "en-us": { "role": { "label": "Contract assets recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r217" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r57", "r113", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r288", "r466" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [ "http://electromed.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Current income tax expense", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r71", "r265", "r271", "r456" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://electromed.com/role/FinancingArrangements" ], "lang": { "en-us": { "role": { "label": "Financing Arrangements", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r68", "r112", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Basis spread on rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "elmd_DebtInstrumentCovenantComplianceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "DebtInstrumentCovenantComplianceAmount", "crdr": "debit", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Minimum tangible net worth to be maintained", "documentation": "This element represent debt instrument covenant compliance amount." } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred income taxes", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r258", "r259" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r4", "r71", "r85", "r270", "r271", "r456" ] }, "elmd_DemonstrationEquipmentReturnedToInventory": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "DemonstrationEquipmentReturnedToInventory", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Demonstration equipment returned to inventory", "documentation": "This element represent demonstration equipment returned to inventory." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r30" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "auth_ref": [ "r461", "r504" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r215", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r215", "r404", "r405", "r406", "r407", "r408", "r409", "r410" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://electromed.com/role/RevenuesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of disaggregated revenue", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r469" ] }, "elmd_DisclosureCommonStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://electromed.com/20240331", "localname": "DisclosureCommonStockAbstract", "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://electromed.com/role/Share-basedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r219", "r223", "r250", "r251", "r252", "r411" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r437" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r435", "r437", "r438" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r436" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r424" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r437" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r437" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r439" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r427" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r108", "r120", "r121", "r122", "r123", "r124", "r128", "r130", "r133", "r134", "r135", "r137", "r286", "r287", "r298", "r309", "r399" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r108", "r120", "r121", "r122", "r123", "r124", "r130", "r133", "r134", "r135", "r137", "r286", "r287", "r298", "r309", "r399" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://electromed.com/role/InterimFinancialReportingPolicies" ], "lang": { "en-us": { "role": { "label": "Net income per common share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r22", "r23" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://electromed.com/role/IncomeTaxesDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Effective tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r261" ] }, "elmd_EmployeeMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "EmployeeMember", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Employee [Member]", "documentation": "This member stands for employee member." } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r430" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r426" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r426" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r443" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r426" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r440" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r438" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r426" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r426" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r426" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r426" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r441" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r6", "r89", "r104", "r105", "r106", "r115", "r116", "r117", "r119", "r125", "r127", "r138", "r160", "r161", "r203", "r253", "r254", "r255", "r266", "r267", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r317", "r318", "r319", "r329", "r387" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finite-life intangible assets, net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r66", "r297" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r56", "r113", "r141", "r146", "r150", "r152", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r288", "r401", "r466" ] }, "us-gaap_GuaranteesAndProductWarrantiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuaranteesAndProductWarrantiesAbstract", "lang": { "en-us": { "role": { "label": "Guarantees and Product Warranties [Abstract]" } } }, "auth_ref": [] }, "elmd_HomeCareDistributorMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "HomeCareDistributorMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Home Care Distributor [Member]", "documentation": "This member stands for home care distributor member." } } }, "auth_ref": [] }, "elmd_HomeCareMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "HomeCareMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Home Care [Member]", "documentation": "This member stands for home care member." } } }, "auth_ref": [] }, "elmd_HospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "HospitalMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Hospital [Member]", "documentation": "This member stands for hospital member." } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Net income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r54", "r77", "r141", "r146", "r150", "r152", "r299", "r307", "r401" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://electromed.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r114", "r257", "r262", "r263", "r264", "r268", "r272", "r273", "r274", "r328" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/IncomeTaxesDetailsNarrative", "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r80", "r86", "r126", "r127", "r144", "r260", "r269", "r310" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r19", "r21" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Taxes paid on stock options exercised on a net basis", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r21" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerAsset", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Contract assets", "label": "Increase (Decrease) in Contract with Customer, Asset", "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r452" ] }, "us-gaap_IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInIncomeTaxesPayableNetOfIncomeTaxesReceivable", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income tax receivable, net", "documentation": "The increase (decrease) during the reporting period in the amounts payable to taxing authorities for taxes that are based on the reporting entity's earnings, net of amounts receivable from taxing authorities for refunds of overpayments or recoveries of income taxes." } } }, "auth_ref": [ "r452" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r3" ] }, "elmd_IntangibleAssetAcquisitionsInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "IntangibleAssetAcquisitionsInAccountsPayable", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Intangible asset acquisitions in accounts payable", "documentation": "This element represent intangible asset acquisitions in accounts payable." } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest income, net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r79" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://electromed.com/role/Inventories" ], "lang": { "en-us": { "role": { "verboseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r163" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "presentation": [ "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r446" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets", "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Inventories", "verboseLabel": "Total", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r100", "r398", "r412" ] }, "us-gaap_InventoryValuationReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryValuationReserves", "crdr": "credit", "presentation": [ "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Reserve for obsolescence", "label": "Inventory Valuation Reserves", "documentation": "Amount of valuation reserve for inventory." } } }, "auth_ref": [ "r27", "r450" ] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "presentation": [ "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Work in process", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r447" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r13", "r113", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r276", "r277", "r278", "r288", "r347", "r400", "r423", "r466", "r499", "r500" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r50", "r76", "r305", "r412", "r455", "r462", "r497" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Shareholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r15", "r92", "r113", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r276", "r277", "r278", "r288", "r412", "r466", "r499", "r500" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other long-term liabilities", "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAxis", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Lender Name [Axis]", "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit." } } }, "auth_ref": [ "r12", "r454" ] }, "us-gaap_LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases", "crdr": "credit", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Available borrowing capacity", "documentation": "The maximum amount of borrowing capacity under a line of credit that is available as of the balance sheet date for a specific purpose other than for financing goods acquired for inventory or imminent delivery to a customer." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLenderDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLenderDomain", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility." } } }, "auth_ref": [ "r12", "r454" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r454" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r12" ] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": [ "r12" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r12", "r454" ] }, "us-gaap_LinesOfCreditCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LinesOfCreditCurrent", "crdr": "credit", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Line of credit balance", "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r42", "r74" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "elmd_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "MedicaidMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Medicaid [Member]", "documentation": "This member stands for medicaid member." } } }, "auth_ref": [] }, "elmd_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "MedicareMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Medicare [Member]", "documentation": "This member stands for medicare member." } } }, "auth_ref": [] }, "elmd_MedicareSupplementalMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "MedicareSupplementalMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Medicare Supplemental [Member]", "documentation": "This member stands for medicare supplemental." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Financing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r110" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Investing Activities" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r60", "r61", "r62" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash Flows From Operating Activities" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://electromed.com/role/StatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows", "http://electromed.com/role/StatementsOfOperations", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "label": "Net income", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r55", "r62", "r78", "r90", "r102", "r103", "r106", "r113", "r118", "r120", "r121", "r122", "r123", "r126", "r127", "r132", "r141", "r146", "r150", "r152", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r287", "r288", "r308", "r369", "r385", "r386", "r401", "r422", "r466" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://electromed.com/role/InterimFinancialReportingPolicies" ], "lang": { "en-us": { "role": { "label": "Recently Issued Accounting Standards", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating expenses" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r141", "r146", "r150", "r152", "r401" ] }, "elmd_OptionExerciseProceedsInOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "OptionExerciseProceedsInOtherAssets", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Option exercise proceeds in other assets", "documentation": "This element represent option exercise proceeds in other assets." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://electromed.com/role/InterimFinancialReporting" ], "lang": { "en-us": { "role": { "label": "Interim Financial Reporting", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } }, "auth_ref": [ "r41", "r63", "r64", "r72" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r94" ] }, "elmd_OtherHomecareMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "OtherHomecareMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Other Homecare [Member]", "documentation": "This member stands for other homecare member." } } }, "auth_ref": [] }, "us-gaap_OtherInventoryInTransit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInventoryInTransit", "crdr": "debit", "presentation": [ "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Estimated inventory to be returned", "documentation": "Gross amount of merchandise or supplies to which the entity holds the title but does not hold physical possession because the goods are currently being transported." } } }, "auth_ref": [ "r449" ] }, "us-gaap_OtherInventorySupplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherInventorySupplies", "crdr": "debit", "presentation": [ "http://electromed.com/role/ComponentsOfInventoryWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Parts inventory", "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r448" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other accrued liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r14", "r412" ] }, "elmd_OtherMember": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "OtherMember", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Other [Member]", "documentation": "This member stands for other member." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r437" ] }, "elmd_PayerTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://electromed.com/20240331", "localname": "PayerTypeAxis", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Payer Type [Axis]" } } }, "auth_ref": [] }, "elmd_PayerTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://electromed.com/20240331", "localname": "PayerTypeDomain", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r18" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Taxes paid on net share settlement of stock option exercises", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r109" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Expenditures for finite-life intangible assets", "label": "Payments to Acquire Intangible Assets", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r59" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Expenditures for property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r59" ] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r431" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r432" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r451" ] }, "elmd_PrimeRate": { "xbrltype": "percentItemType", "nsuri": "http://electromed.com/20240331", "localname": "PrimeRate", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Interest rate", "documentation": "This element represent prime rate." } } }, "auth_ref": [] }, "us-gaap_PrimeRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrimeRateMember", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Prime Rate [Member]", "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of options", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r2", "r9" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r153", "r296", "r311", "r312", "r313", "r314", "r315", "r316", "r396", "r404", "r413", "r445", "r464", "r465", "r469", "r502" ] }, "us-gaap_ProductWarrantyAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrual", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets", "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Warranty reserve", "periodStartLabel": "Warranty reserve, beginning", "periodEndLabel": "Warranty reserve, ending", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers." } } }, "auth_ref": [ "r36", "r170", "r174", "r177" ] }, "us-gaap_ProductWarrantyAccrualPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualPayments", "crdr": "debit", "presentation": [ "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Expenditures and costs incurred for warranty claims", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty." } } }, "auth_ref": [ "r175" ] }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyAccrualWarrantiesIssued", "crdr": "credit", "presentation": [ "http://electromed.com/role/ChangesInCompanysWarrantyReserveWereAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Accrual for products sold", "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued." } } }, "auth_ref": [ "r176" ] }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductWarrantyDisclosureTextBlock", "presentation": [ "http://electromed.com/role/WarrantyReserve" ], "lang": { "en-us": { "role": { "label": "Warranty Reserve", "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period." } } }, "auth_ref": [ "r166", "r167", "r168", "r169", "r171", "r172" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "auth_ref": [ "r153", "r296", "r311", "r312", "r313", "r314", "r315", "r316", "r396", "r404", "r413", "r445", "r464", "r465", "r469", "r502" ] }, "elmd_PropertyAndEquipmentAcquisitionsInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "PropertyAndEquipmentAcquisitionsInAccountsPayable", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Property and equipment acquisitions in accounts payable", "documentation": "This element represent property and equipment acquisitions in accounts payable." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r300", "r306", "r412" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r40", "r256", "r501" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r22" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained earnings", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r47", "r69", "r304", "r320", "r321", "r327", "r350", "r412" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r89", "r115", "r116", "r117", "r119", "r125", "r127", "r160", "r161", "r253", "r254", "r255", "r266", "r267", "r279", "r281", "r282", "r284", "r285", "r317", "r319", "r329", "r506" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://electromed.com/role/ScheduleOfDisaggregatedRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r142", "r143", "r145", "r148", "r149", "r153", "r154", "r155", "r214", "r215", "r296" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://electromed.com/role/Revenues" ], "lang": { "en-us": { "role": { "label": "Revenues", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r87", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r218" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r107", "r113", "r142", "r143", "r145", "r148", "r149", "r153", "r154", "r155", "r159", "r178", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r288", "r299", "r466" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://electromed.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "label": "The components of inventory were as follows:", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r10", "r51", "r52", "r53" ] }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "presentation": [ "http://electromed.com/role/WarrantyReserveTables" ], "lang": { "en-us": { "role": { "label": "Changes in the Company\u2019s warranty reserve were as follows:", "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r220", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://electromed.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Stock option transactions during the nine months ended March 31, 2024, are summarized as follows:", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r7", "r8", "r32" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://electromed.com/role/Share-basedCompensationTables" ], "lang": { "en-us": { "role": { "label": "The following assumptions were used to estimate the fair value of stock options granted:", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r70" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r425" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r429" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r428" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r433" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r58" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://electromed.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vesting term", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Fair value of per share", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r238" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Restricted stock - unvested", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r235", "r236" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Weight average fair value - unvested restricted stock (per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r235", "r236" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "presentation": [ "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Expected volatility - maximum", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum", "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "presentation": [ "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Expected volatility - maximum", "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "presentation": [ "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate - maximum", "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "presentation": [ "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Risk free interest rate - minimum", "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r220", "r222", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Vested and exercisable", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r229" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cancelled or Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Cancelled or Forfeited", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Granted", "verboseLabel": "Shares granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r231" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Options exercisable, intrinsic value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r31" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Option outstanding , beginning", "periodEndLabel": "Option outstanding, ending", "label": "Shares outstanding", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r227", "r228" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Other description", "documentation": "Description of modification of award under share-based payment arrangement. Includes, but is not limited to, terms for expiration date, vesting rights and exercise price." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Exercised", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r232" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r231" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://electromed.com/role/FollowingAssumptionsWereUsedToEstimateFairValueOfStockOptionsGrantedDetails" ], "lang": { "en-us": { "role": { "label": "Expected term (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r245" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Options exercisable, intrinsic value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r31" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Weighted average grant date fair value, beginning", "periodEndLabel": "Weighted average grant date fair value, ending", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price", "documentation": "Weighted average grant-date fair value of non-vested options outstanding." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "verboseLabel": "Unrecognized compensation expense, period for recognition", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r244" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense, period for recognition", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r243" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r434" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r88", "r96", "r97", "r98", "r113", "r130", "r131", "r133", "r135", "r139", "r140", "r159", "r178", "r180", "r181", "r182", "r185", "r186", "r198", "r199", "r200", "r201", "r202", "r288", "r323", "r324", "r325", "r326", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r349", "r370", "r387", "r390", "r391", "r392", "r393", "r394", "r444", "r453", "r460" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r6", "r17", "r89", "r104", "r105", "r106", "r115", "r116", "r117", "r119", "r125", "r127", "r138", "r160", "r161", "r203", "r253", "r254", "r255", "r266", "r267", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r317", "r318", "r319", "r329", "r387" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r115", "r116", "r117", "r138", "r296", "r322", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r363", "r364", "r365", "r366", "r368", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r417" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r115", "r116", "r117", "r138", "r296", "r322", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r362", "r363", "r364", "r365", "r366", "r368", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r387", "r417" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Stock issued", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": [ "r6", "r69" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted stock (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r6", "r44", "r45", "r69" ] }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Forfeiture of restricted stock (in shares)", "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r6", "r44", "r45", "r69" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity", "http://electromed.com/role/StockOptionTransactionsDuringNineMonthsEndedMarch312024AreSummarizedAsFollowsDetails" ], "lang": { "en-us": { "role": { "label": "Issuance of common stock upon exercise of options (in shares)", "negatedLabel": "Exercised", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r6", "r44", "r45", "r69", "r232" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Forfeiture of restricted stock", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": [ "r6", "r44", "r45", "r69" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "label": "Issuance of restricted stock", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r6", "r69" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Issuance of common stock upon exercise of options", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r6", "r17", "r69" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodShares", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock (in shares)", "label": "Number of share repurchased", "documentation": "Number of shares that have been repurchased and retired during the period." } } }, "auth_ref": [ "r6", "r44", "r45", "r69" ] }, "us-gaap_StockRepurchasedAndRetiredDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedAndRetiredDuringPeriodValue", "crdr": "debit", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Repurchase of common stock", "documentation": "Equity impact of the value of stock that has been repurchased and retired during the period. The excess of the purchase price over par value can be charged against retained earnings (once the excess is fully allocated to additional paid in capital)." } } }, "auth_ref": [ "r6", "r44", "r45", "r69" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://electromed.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://electromed.com/role/BalanceSheets", "http://electromed.com/role/StatementsOfShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders' equity", "periodStartLabel": "Balance on December 31, 2023", "periodEndLabel": "Balance on March 31, 2024", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r45", "r48", "r49", "r65", "r351", "r367", "r388", "r389", "r412", "r423", "r455", "r462", "r497", "r506" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://electromed.com/role/BalanceSheets" ], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://electromed.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Disclosures of Cash Flow Information" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "auth_ref": [ "r461", "r498" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://electromed.com/role/CommonStockDetailsNarrative", "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "elmd_UnrecognizedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://electromed.com/20240331", "localname": "UnrecognizedCompensationExpense", "crdr": "debit", "presentation": [ "http://electromed.com/role/Share-basedCompensationDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Unrecognized compensation expense", "documentation": "This element represent unrecognized compensation expense." } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://electromed.com/role/InterimFinancialReportingPolicies" ], "lang": { "en-us": { "role": { "label": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r24", "r25", "r26", "r81", "r82", "r83", "r84" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://electromed.com/role/FinancingArrangementsDetailsNarrative" ], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r129", "r135" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r128", "r135" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://electromed.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted-average common shares outstanding:" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://electromed.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r442" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "330", "SubTopic": "10", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB TOPIC 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "805", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479835/944-805-50-3" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "944", "SubTopic": "805", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479805/944-805-55-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r397": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r400": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r401": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r402": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r403": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r404": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r405": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r406": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r407": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r408": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r409": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r410": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r411": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r413": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r416": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r421": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r422": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r423": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r424": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r425": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r426": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r428": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r430": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r431": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r432": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r433": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r434": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r435": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r436": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r437": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r438": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r439": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r440": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r441": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r442": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r443": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r444": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r445": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r446": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r447": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r450": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r453": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r456": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r457": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r458": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r459": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r460": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r461": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r462": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r463": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r464": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r465": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r466": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r467": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r468": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r469": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r470": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r497": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r498": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r500": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r501": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r502": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r503": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r504": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r505": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r506": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r507": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" } } } ZIP 51 0000897101-24-000163-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000897101-24-000163-xbrl.zip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end XML 53 elmd240512_10q_htm.xml IDEA: XBRL DOCUMENT 0001488917 2023-07-01 2024-03-31 0001488917 2024-05-02 0001488917 2024-03-31 0001488917 2023-06-30 0001488917 2024-01-01 2024-03-31 0001488917 2023-01-01 2023-03-31 0001488917 2022-07-01 2023-03-31 0001488917 2022-06-30 0001488917 2023-03-31 0001488917 us-gaap:CommonStockMember 2022-06-30 0001488917 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001488917 us-gaap:RetainedEarningsMember 2022-06-30 0001488917 us-gaap:CommonStockMember 2022-09-30 0001488917 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001488917 us-gaap:RetainedEarningsMember 2022-09-30 0001488917 2022-09-30 0001488917 us-gaap:CommonStockMember 2022-12-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001488917 us-gaap:RetainedEarningsMember 2022-12-31 0001488917 2022-12-31 0001488917 us-gaap:CommonStockMember 2023-06-30 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001488917 us-gaap:RetainedEarningsMember 2023-06-30 0001488917 us-gaap:CommonStockMember 2023-09-30 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001488917 us-gaap:RetainedEarningsMember 2023-09-30 0001488917 2023-09-30 0001488917 us-gaap:CommonStockMember 2023-12-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001488917 us-gaap:RetainedEarningsMember 2023-12-31 0001488917 2023-12-31 0001488917 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001488917 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001488917 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001488917 2022-07-01 2022-09-30 0001488917 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001488917 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001488917 2022-10-01 2022-12-31 0001488917 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001488917 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001488917 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001488917 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001488917 2023-07-01 2023-09-30 0001488917 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001488917 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001488917 2023-10-01 2023-12-31 0001488917 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001488917 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001488917 us-gaap:CommonStockMember 2023-03-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001488917 us-gaap:RetainedEarningsMember 2023-03-31 0001488917 us-gaap:CommonStockMember 2024-03-31 0001488917 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001488917 us-gaap:RetainedEarningsMember 2024-03-31 0001488917 elmd:HomeCareMember 2024-01-01 2024-03-31 0001488917 elmd:HomeCareMember 2023-01-01 2023-03-31 0001488917 elmd:HomeCareMember 2023-07-01 2024-03-31 0001488917 elmd:HomeCareMember 2022-07-01 2023-03-31 0001488917 elmd:HospitalMember 2024-01-01 2024-03-31 0001488917 elmd:HospitalMember 2023-01-01 2023-03-31 0001488917 elmd:HospitalMember 2023-07-01 2024-03-31 0001488917 elmd:HospitalMember 2022-07-01 2023-03-31 0001488917 elmd:HomeCareDistributorMember 2024-01-01 2024-03-31 0001488917 elmd:HomeCareDistributorMember 2023-01-01 2023-03-31 0001488917 elmd:HomeCareDistributorMember 2023-07-01 2024-03-31 0001488917 elmd:HomeCareDistributorMember 2022-07-01 2023-03-31 0001488917 elmd:OtherMember 2024-01-01 2024-03-31 0001488917 elmd:OtherMember 2023-01-01 2023-03-31 0001488917 elmd:OtherMember 2023-07-01 2024-03-31 0001488917 elmd:OtherMember 2022-07-01 2023-03-31 0001488917 elmd:CommercialMember elmd:HomeCareMember 2024-01-01 2024-03-31 0001488917 elmd:CommercialMember elmd:HomeCareMember 2023-01-01 2023-03-31 0001488917 elmd:CommercialMember elmd:HomeCareMember 2023-07-01 2024-03-31 0001488917 elmd:CommercialMember elmd:HomeCareMember 2022-07-01 2023-03-31 0001488917 elmd:MedicareMember elmd:HomeCareMember 2024-01-01 2024-03-31 0001488917 elmd:MedicareMember elmd:HomeCareMember 2023-01-01 2023-03-31 0001488917 elmd:MedicareMember elmd:HomeCareMember 2023-07-01 2024-03-31 0001488917 elmd:MedicareMember elmd:HomeCareMember 2022-07-01 2023-03-31 0001488917 elmd:MedicareSupplementalMember elmd:HomeCareMember 2024-01-01 2024-03-31 0001488917 elmd:MedicareSupplementalMember elmd:HomeCareMember 2023-01-01 2023-03-31 0001488917 elmd:MedicareSupplementalMember elmd:HomeCareMember 2023-07-01 2024-03-31 0001488917 elmd:MedicareSupplementalMember elmd:HomeCareMember 2022-07-01 2023-03-31 0001488917 elmd:MedicaidMember elmd:HomeCareMember 2024-01-01 2024-03-31 0001488917 elmd:MedicaidMember elmd:HomeCareMember 2023-01-01 2023-03-31 0001488917 elmd:MedicaidMember elmd:HomeCareMember 2023-07-01 2024-03-31 0001488917 elmd:MedicaidMember elmd:HomeCareMember 2022-07-01 2023-03-31 0001488917 elmd:OtherHomecareMember elmd:HomeCareMember 2024-01-01 2024-03-31 0001488917 elmd:OtherHomecareMember elmd:HomeCareMember 2023-01-01 2023-03-31 0001488917 elmd:OtherHomecareMember elmd:HomeCareMember 2023-07-01 2024-03-31 0001488917 elmd:OtherHomecareMember elmd:HomeCareMember 2022-07-01 2023-03-31 0001488917 2022-07-01 2023-06-30 0001488917 us-gaap:RevolvingCreditFacilityMember 2024-03-31 0001488917 us-gaap:RevolvingCreditFacilityMember 2023-06-30 0001488917 us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2024-03-31 0001488917 us-gaap:RevolvingCreditFacilityMember 2023-07-01 2024-03-31 0001488917 elmd:CapitalStockMember 2024-03-31 0001488917 elmd:AuthorizedSharesUndesignatedStockMember 2024-03-31 0001488917 srt:BoardOfDirectorsChairmanMember 2022-05-26 0001488917 us-gaap:EmployeeStockOptionMember 2023-07-01 2024-03-31 0001488917 us-gaap:EmployeeStockOptionMember 2024-03-31 0001488917 us-gaap:RestrictedStockMember elmd:EmployeeMember 2023-07-01 2024-03-31 0001488917 srt:DirectorMember us-gaap:RestrictedStockMember 2023-07-01 2024-03-31 0001488917 us-gaap:RestrictedStockMember 2024-03-31 0001488917 us-gaap:RestrictedStockMember 2023-07-01 2024-03-31 0001488917 us-gaap:RestrictedStockUnitsRSUMember 2023-07-01 2024-03-31 0001488917 us-gaap:RestrictedStockUnitsRSUMember 2022-07-01 2023-03-31 0001488917 us-gaap:RestrictedStockUnitsRSUMember 2024-03-31 0001488917 us-gaap:EmployeeStockOptionMember 2023-06-30 iso4217:USD shares iso4217:USD shares pure false 2024 Q3 --06-30 0001488917 487000 487000 468000 1217000 0 0 3000000 P6Y P6Y P6Y8M12D P2Y9M18D P3Y P1Y4M24D P3Y2M30D 10-Q true 2024-03-31 false 001-34839 Electromed, Inc. MN 41-1732920 500 Sixth Avenue NW New Prague MN 56071 (952) 758-9299 Common Stock, $0.01 par value ELMD NYSEAMER Yes Yes Non-accelerated Filer true false false 8655727 11712000 7372000 45000 45000 23907000 24130000 642000 487000 4178000 4221000 592000 1577000 291000 41322000 37787000 5283000 5672000 648000 605000 106000 161000 1542000 1581000 48901000 45806000 792000 1372000 2987000 3018000 336000 1525000 1378000 1022000 1949000 6326000 8053000 31000 86000 6357000 8139000 0.01 0.01 13000000 13000000 8655727 8655727 8555238 8555238 87000 86000 20342000 18788000 22115000 18793000 42544000 37667000 48901000 45806000 13871000 12068000 39884000 34455000 3489000 3012000 9459000 8386000 10382000 9056000 30425000 26069000 8374000 7694000 25699000 22937000 167000 166000 480000 618000 8541000 7860000 26179000 23555000 1841000 1196000 4246000 2514000 120000 26000 293000 37000 1961000 1222000 4539000 2551000 468000 147000 1217000 418000 1493000 1075000 3322000 2133000 0.17 0.13 0.39 0.25 0.17 0.12 0.38 0.25 8565725 8461531 8549352 8449623 8892821 8710106 8822938 8694407 3322000 2133000 594000 370000 37000 52000 1250000 506000 39000 32000 -223000 1293000 155000 284000 -78000 264000 -1234000 -105000 -627000 -270000 -1386000 -111000 31000 660000 4578000 316000 265000 1221000 84000 54000 -349000 -1275000 111000 40000 305000 153000 111000 -418000 4340000 -1377000 7372000 8153000 11712000 6776000 1806000 655000 35000 136000 6000 194000 35000 9000 8475438 85000 18308000 15780000 34173000 81000 81000 27400 -14166 11760 -60000 -60000 95000 95000 14568 145000 145000 8485864 85000 18343000 15716000 34144000 977000 977000 26000 3100 16000 16000 221000 221000 800 8000 8000 8514164 85000 18580000 16685000 35350000 1075000 1075000 42436 1000 23000 24000 -245000 -245000 190000 190000 8556600 86000 18548000 17760000 36394000 8555238 86000 18788000 18793000 37667000 155000 155000 20878 2934 29000 29000 371000 371000 8579050 86000 19188000 18948000 38222000 1674000 1674000 21000 2627 26000 26000 420000 420000 8602677 86000 19634000 20622000 40342000 1493000 1493000 2550 50500 1000 249000 250000 459000 459000 8655727 87000 20342000 22115000 42544000 <p id="xdx_80E_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zjQfukQE7kYe" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Note 1. Interim Financial Reporting Nature of business: Electromed, Inc. (the “Company”) develops, manufactures, and markets innovative airway clearance products that apply High Frequency Chest Wall Oscillation (“HFCWO”) therapy for pulmonary care patients. The Company markets its products in the U.S. to the homecare and hospital markets. The Company also sells internationally through distributors. Since its inception, the Company has operated in a single industry segment: developing, manufacturing, and marketing medical equipment. Basis of presentation: The accompanying unaudited Condensed Financial Statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. In the opinion of management, the accompanying unaudited Condensed Financial Statements reflect all adjustments consisting of normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations as required by Regulation S-X. Interim results of operations are not necessarily indicative of the results that may be achieved for the full year. The financial statements and related notes do not include all information and footnotes required by U.S. GAAP for annual reports. This interim report should be read in conjunction with the financial statements included in the Company’s <a href="http://www.sec.gov/Archives/edgar/data/1488917/000089710123000380/elmd230887_10k.htm">Annual Report on Form 10-K for the fiscal year ended June 30, 2023</a> (“fiscal 2023”). A summary of the Company’s significant accounting policies follows: Use of estimates. Management uses estimates and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation and warranty reserve. Net income per common share. Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20240101__20240331_zxa28kHzqBv2" title="Common stock equivalents included from calculation of diluted earnings per share">289,362 and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zmfoWFlgOKTi" title="Common stock equivalents included from calculation of diluted earnings per share">179,992 for the three months ended March 31, 2024, and 2023, respectively, and were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230701__20240331_zzIr2lSTSbgj" title="Common stock equivalents included from calculation of diluted earnings per share">400,639 and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zyBlI8D51f16" title="Common stock equivalents included from calculation of diluted earnings per share">200,140 for the nine months ended March 31, 2024, and 2023, respectively. Recently Issued Accounting Standards In June 2016, the Financial Accounting Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments -- Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. The company adopted the standard effective July 1, 2023. The Company’s adoption of the standard did not have a material impact on the financial statements. Use of estimates. Management uses estimates and assumptions in preparing the unaudited Condensed Financial Statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could vary from the estimates that were used. The Company believes the critical accounting policies that require the most significant assumptions and judgments in the preparation of its unaudited Condensed Financial Statements include revenue recognition and the related estimation of variable consideration, inventory valuation, share-based compensation and warranty reserve. Net income per common share. Net income is presented on a per share basis for both basic and diluted common shares. Basic net income per common share is computed using the weighted average number of common shares outstanding during the period, excluding any restricted stock awards which have not vested. The diluted net income per common share calculation includes outstanding restricted stock grants and assumes that all stock options were exercised and converted into common stock at the beginning of the period unless their effect would be anti-dilutive. Common stock equivalents excluded from the calculation of diluted earnings per share because their impact was anti-dilutive were <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20240101__20240331_zxa28kHzqBv2" title="Common stock equivalents included from calculation of diluted earnings per share">289,362 and <span id="xdx_90C_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230101__20230331_zmfoWFlgOKTi" title="Common stock equivalents included from calculation of diluted earnings per share">179,992 for the three months ended March 31, 2024, and 2023, respectively, and were <span id="xdx_90E_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20230701__20240331_zzIr2lSTSbgj" title="Common stock equivalents included from calculation of diluted earnings per share">400,639 and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220701__20230331_zyBlI8D51f16" title="Common stock equivalents included from calculation of diluted earnings per share">200,140 for the nine months ended March 31, 2024, and 2023, respectively. 289362 179992 400639 200140 Recently Issued Accounting Standards In June 2016, the Financial Accounting Board issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments -- Credit Losses: Measurement of Credit Losses on Financial Instruments, which was subsequently amended by ASU 2018-19, ASU 2019-04, 2019-05, 2019-10, 2019-11, and 2020-02. The standard introduces new accounting guidance for credit losses on financial instruments within its scope, including trade receivables. This new guidance adds an impairment model that is based on expected losses rather than incurred losses. The company adopted the standard effective July 1, 2023. The Company’s adoption of the standard did not have a material impact on the financial statements. Note 2. Revenues Revenue is measured based on consideration specified in the contract with a customer, adjusted for any applicable estimates of variable consideration and other factors affecting the transaction price, including consideration paid or payable from customers and significant financing components. Revenue from all customers is recognized when a performance obligation is satisfied by transferring control of a distinct good or service to a customer, as further described below under Performance obligations and transaction price. Individual promised goods and services in a contract are considered a performance obligation and accounted for separately if the individual good or service is distinct (i.e., the customer can benefit from the good or service on its own or with other resources that are readily available to the customer and the good or service is separately identifiable from other promises in the arrangement). If an arrangement includes multiple performance obligations, the consideration is allocated between the performance obligations in proportion to their estimated standalone selling price, unless discounts or variable consideration is attributable to one or more but not all the performance obligations. Costs related to products delivered are recognized in the period incurred, unless criteria for capitalization of costs under Accounting Standards Codification (“ASC”) 340-40, “Other Assets and Deferred Costs” (“ASC 340”), or other applicable guidance are met. The Company includes shipping and handling fees in net revenues. Shipping and handling costs associated with the shipment of the Company’s SmartVest® Airway Clearance System (“SmartVest System”) after control has transferred to a customer are accounted for as a fulfillment cost and are included in cost of revenues in the Condensed Statements of Operations. The timing of revenue recognition, billings and cash collections results in accounts receivable on the Condensed Balance Sheets as further described below under Accounts receivable and Contract assets. Disaggregation of revenues. In the following table, net revenues are disaggregated by market: Schedule of disaggregated revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 40%">Homecare</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zb2UP9ZVab3g" style="width: 12%; text-align: right" title="Revenue">12,287,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zjkmOf0nEMle" style="width: 12%; text-align: right" title="Revenue">10,971,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVbwuDJi2MRa" style="width: 12%; text-align: right" title="Revenue">36,108,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zfrwEQ4Zrb3c" style="width: 12%; text-align: right" title="Revenue">31,335,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Hospital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HospitalMember_zs8rQmfE2Uv3" style="text-align: right" title="Revenue">783,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HospitalMember_zSHzwlrkZtD7" style="text-align: right" title="Revenue">440,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HospitalMember_zDbBGUTMI8u7" style="text-align: right" title="Revenue">1,909,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HospitalMember_zMkyeMYnUXqe" style="text-align: right" title="Revenue">1,420,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Homecare distributor</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_z2wSBiYErAc8" style="text-align: right" title="Revenue">524,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zI6WKVFbCvo9" style="text-align: right" title="Revenue">501,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zOp5lICpib6f" style="text-align: right" title="Revenue">1,377,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_z2kg54hFSkVf" style="text-align: right" title="Revenue">1,391,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--OtherMember_zhoJvfEKJhwg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">277,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_zeTuaNLyXpT4" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">156,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--OtherMember_z2c5IYzhqtB3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">490,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--OtherMember_ztygcsdQfLu1" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">309,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331_z35ClQhHsqB" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">13,871,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_z0826JTQ8ZCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">12,068,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331_znGpZ9RH45wd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">39,884,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zMVXCTUgn2L8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">34,455,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> In the following table, net homecare revenue is disaggregated by payer type: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 40%">Commercial</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_z3FshHLLZox2" style="width: 12%; text-align: right" title="Revenue">5,974,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zNztYVFAd3Pl" style="width: 12%; text-align: right" title="Revenue">4,787,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zyNGIuB06hmg" style="width: 12%; text-align: right" title="Revenue">17,684,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 3%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_z9OHZZ3bdRJ4" style="width: 10%; text-align: right" title="Revenue">12,706,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medicare</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zlblrwdW41q6" style="text-align: right" title="Revenue">4,825,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zf8Q92XH3asg" style="text-align: right" title="Revenue">4,544,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_znu5G9A0D17f" style="text-align: right" title="Revenue">13,666,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEpFbPGThO28" style="text-align: right" title="Revenue">13,753,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Medicare Supplemental</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_zUOuGSlWrbc1" style="text-align: right" title="Revenue">1,177,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_zx5rK7eSEQa5" style="text-align: right" title="Revenue">1,278,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_zRBBvfjCBuCl" style="text-align: right" title="Revenue">3,447,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_ztr8sQ6lYtI7" style="text-align: right" title="Revenue">3,681,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medicaid</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zDCA42myitga" style="text-align: right" title="Revenue">115,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zX1X0Z3IedM1" style="text-align: right" title="Revenue">128,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z2mzwLbUhqKd" style="text-align: right" title="Revenue">722,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zgLZqDy147rf" style="text-align: right" title="Revenue">618,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt">Other homecare</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zZqv2Ugx4Zo7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">196,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zqUDOsiDoHib" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">234,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zkok32gUOPBi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">589,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zVHqwBbfGow6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">577,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zodYspyRdxWa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">12,287,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zHypqSaYIDz1" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">10,971,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zmbXcUVQfHW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">36,108,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z7WOy74kQurf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">31,335,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> Revenues are recognized at a point in time when control passes to the customer upon product shipment or delivery. Performance obligations and transaction price. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account under ASC 606, “Revenue From Contracts With Customers” (“ASC 606”). A contract’s transaction price is allocated to each distinct performance obligation in proportion to the standalone selling price for each and recognized as revenue when, or as, the performance obligation is satisfied. The Company’s performance obligations and the timing or method of revenue recognition in each of the Company’s markets are discussed below: Homecare market. In the Company’s homecare market, its customers are patients who use the SmartVest System. The various models of the SmartVest System are comprised of three main components – a generator, a vest and a connecting hose – that are sold together as an integrated unit. Accordingly, in contracts within the homecare market, the Company regards the SmartVest System to be a single performance obligation. The Company makes available to its homecare patients limited post-sale services that are not material in the context of the contracts, either individually or taken together, and therefore does not consider them to be performance obligations. The costs associated with the services are accrued and expensed when the related revenues are recognized. As such, transactions in the homecare market consist of a single performance obligation: the SmartVest System. Homecare patients generally will rely on third-party payers, including commercial payers and governmental payers such as Medicare, Medicaid and the U.S. Department of Veterans Affairs to cover and reimburse all or part of the cost of the SmartVest System. The third-party payers’ reimbursement programs fall into three types, distinguished by the differences in the timing of payments from the payer, consisting of either (i) outright sale, in which payment is received from the payer based on standard terms, (ii) capped installment sale, under which the SmartVest System is sold for a series of payments that are capped not to exceed a prescribed or negotiated amount over a period of time or (iii) installment sale, under which the SmartVest System is paid for over a period of several months as long as the patient continues to use the SmartVest System. Regardless of the type of transaction, provided criteria for an enforceable contract are met, it is the Company’s long- standing business practice to regard all homecare agreements as transferring control to the patient upon shipment or delivery, despite possible payment cancellation under government or commercial programs where the payer is controlling the payment over specified time periods. For homecare sales that feature installment payments, the ultimate amount of consideration received from Medicare, Medicaid or commercial payers can be significantly less than expected if the contract is terminated due to changes in the patient’s status, including insurance coverage, hospitalization, death or otherwise becoming unable to use the SmartVest System. However, once delivered to a patient who needs the SmartVest System, the patient is under no obligation to return the SmartVest System should payments be terminated because of the described contingencies. As a result, the Company’s product sales qualify for point-in-time revenue recognition. Control transfers to the patient, and revenue is recognized, upon shipment of the SmartVest System. At this point, physical possession and the significant risks and rewards of ownership are transferred to the patient and either a current or future right to payment is triggered, as further discussed under Accounts receivable and Contract assets below. The Company’s contractually stated transaction prices in the homecare market are generally set by the terms of the contracts negotiated with insurance companies or by government programs. The transaction price for the Company’s products may be further impacted by variable consideration. ASC 606 requires the Company to adjust the transaction price at contract inception and throughout the contract duration for the estimated value of payments to be received from insurance payers based on historical experience and other available information, subject to the constraint on estimates of variable consideration. Transactions requiring estimates of variable consideration primarily include (i) capped installment payments, which are subject to the third-party payer’s termination due to changes in insurance coverage, death or the patient’s discontinued use of the SmartVest System, (ii) contracts under appeal and (iii) patient responsibility amounts for deductibles, coinsurance, copays and other similar payments. Although estimates may be made on a contract-by-contract basis, whenever possible, the Company uses all available information, including historical collection patterns, to estimate variable consideration for portfolios of contracts. The Company’s estimates of variable consideration consist of amounts it may receive from insurance providers in excess of its initial revenue estimate due to patients meeting deductibles or coinsurance during the payment duration, changes to a patient’s insurance status, changes in an insurance allowable, claims in appeals with Medicare and amounts received directly from patients for their allowable or coinsurance. The Company believes it has representative historical information to estimate the amount of variable consideration in relevant portfolios considering the significant experience it has with each portfolio and the similarity of patient accounts within a portfolio. The analysis includes steps to ensure that revenue recognized on a portfolio basis does not result in a material difference when compared with an individual contract approach. The Company also leverages its historical experience and all available relevant information for each portfolio of contracts to minimize the risk its estimates used to arrive at the transaction price will result in a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is subsequently resolved. Variable consideration is included in the transaction price if, in the Company’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. For example, for contracts in which the Company believes the criteria for reimbursement under government or commercial payer contracts have been met but for which coverage is unconfirmed or payments are under appeal, the Company has significant observable evidence of relatively consistent claims recovery experience over the prior three to five years. The Company believes the low volatility in historical claims approval rates for populations of patients whose demographics are similar to those of current patients provides reliable predictive value in arriving at estimates of variable consideration in such contracts. Similarly, historical payment trends for recovery of claims subject to payer installments and payments from patients have remained relatively consistent over the past five years. No significant changes in patient demographics or other relevant factors have occurred that would limit the predictive value of such payment trends in estimating variable consideration for current contracts. As a result, the Company believes its estimates of variable consideration are generally not subject to the risk of significant revenue reversal. For each type of variable consideration discussed above, there are many contracts with similar characteristics with a wide range of possible transaction prices. For that reason, the Company uses the probability-weighted expected value method provided under ASC 606 to estimate variable consideration. The Company often receives payment from third-party payers for SmartVest System sales over a period of time that may exceed one year. Despite these extended payment terms, no significant financing component is deemed to exist because the purpose of such terms is not to provide financing to the patient, the payer or the Company. Rather, the extended payment terms are mandated by the government or commercial insurance programs; the fundamental purpose of which is to avoid paying the full purchase price of equipment that may potentially be used by the patient for only a short period of time. Homecare distributors. Sales to distributors, who sell direct to patients, are made at fixed contract prices and may include tiered pricing structures or volume-based rebates which offer more favorable pricing once certain volumes are achieved per the negotiated contract. The distributor’s purchases accumulate to give the distributor the right to a higher discount on purchases more than the specified level within the contract period. As a result, to the extent the Company expects the distributor to exceed the specified volume of purchases in the annual period, it recognizes revenue at a blended rate based on estimated total annual volume and sales revenue. This effectively defers a portion of the transaction price on initial purchases below the specified volumes for recognition when the higher discount is earned on purchases in excess of specified volumes. Transfer of control of the products occurs upon shipment or delivery to the distributor, as applicable. Hospital market. The Company’s hospital sales are made to hospitals and other clinics. Sales to these hospitals are negotiated with the individual hospital or with group purchasing organizations, with payments received directly from the hospital. No insurance reimbursement is involved. Generators are either sold or leased to the hospitals and associated hoses and wraps (used in hospital settings rather than vests) are sold separately. Accordingly, each product is distinct and considered a separate performance obligation in sales to hospital customers. The agreements with hospitals fall into two main types, distinguished by differences in the timing of transfer of control and timing of payments: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">Outright sale – Under these transactions, the Company sells its products for a prescribed or negotiated price. Transfer of control of the product, and associated revenue recognition, occurs at the time of shipment and payment is made within normal credit terms, usually within thirty days.</td> </tr></table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">Wrap usage agreements – Under these transactions, the Company provides a generator device at no cost to the hospital in return for a fixed annual commitment to purchase consumable wraps. These agreements are cancellable upon at least sixty days prior written notice by either party. If cancelled, the generator is returned to the Company, where it can be refurbished and used again later. Revenue for the consumable wraps is recognized when control transfers to the customer.</td> </tr></table> Other. Other revenue consists of international sales which are made directly to several independent distributors at fixed contract prices that are not subject to further adjustments for variable consideration or sales to other customers that do not fall into the markets described above. Transfer of control of the products occurs upon shipment or delivery to the distributor or customer, as applicable. Product warranty. The Company offers warranties on its products. These warranties are assurance-type warranties not sold on a standalone basis or are otherwise considered immaterial in the context of the contract, and therefore are not considered distinct performance obligations under ASC 606. The Company estimates the costs that may be incurred under its warranties and records a liability in the amount of such costs at the time the product is sold. Accounts receivable. The Company’s accounts receivable balance is comprised of amounts due from individuals, -hospitals, and distributors. Balances due from individuals are typically remitted to the Company by third-party reimbursement agencies such as Medicare, Medicaid, and private insurance companies. Accounts receivables are carried at amounts estimated to be received from patients under reimbursement arrangements with third-party payers. Accounts receivable is also net of an allowance for credit losses. Management determines the allowance for credit losses by regularly evaluating individual customer accounts and determining expected losses. Contract assets. Contract assets include amounts recognized as revenue that are estimates of variable consideration for Medicare appeals where the final determination of the insurance coverage amount is dependent on future approval of an appeal, or when the consideration due to the Company is dependent on a future event such as the patient meeting a deductible prior to the Company’s claim being processed by the payer. Contract assets are classified as current as amounts will turn into accounts receivable and be collected during the Company’s normal business operating cycle. Contract assets are reclassified to accounts receivable when the right to receive payment is unconditional. Contract balances. The following table provides information about contract assets from contracts with customers: Schedule of contract asset <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (decrease)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (decrease)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Contract assets, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_dxL_c20230701__20240331_zv1oZBnygtk9" style="width: 12%; text-align: right" title="Contract assets beginning::XDX::487000">487,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_dxL_c20220701__20230630_zuBZqz1paEH5" style="width: 12%; text-align: right" title="Contract assets beginning::XDX::487000">286,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reclassification of contract assets to accounts receivable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230701__20240331_z64D1L1GMXt8" style="text-align: right" title="Reclassification of contract assets to accounts receivable">(1,453,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230630_z4ZnjKHBxxjj" style="text-align: right" title="Reclassification of contract assets to accounts receivable">(1,220,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Contract assets recognized</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230701__20240331_z2DTtAMTRyJb" style="text-align: right" title="Contract assets recognized">1,829,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230630_zMmjjLmb51mi" style="text-align: right" title="Contract assets recognized">1,351,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20230701__20240331_zYPKAt8T7Fji" style="border-bottom: Black 1pt solid; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period">(221,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230630_ztHIeWI5cINi" style="border-bottom: Black 1pt solid; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period">70,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 2.5pt">Contract assets, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20230701__20240331_z6M1GXpOeKKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract assets, ending">642,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230630_zYeC1LQ8Bud3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract assets, ending">487,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Incremental costs to obtain a contract. Sales incentives paid to sales representatives are eligible for capitalization as they are incremental costs that would not have been incurred without entering into a specific sales arrangement and are recoverable through the expected margin on the transaction. However, the recovery period is less than one year as the performance obligation is satisfied upon shipment or delivery. Consequently, the Company applies the practical expedient provided by ASC 340 and expenses sales incentives as incurred. These costs are included in selling, general and administrative expenses in the Condensed Statements of Operations. Disaggregation of revenues. In the following table, net revenues are disaggregated by market: Schedule of disaggregated revenue <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 40%">Homecare</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zb2UP9ZVab3g" style="width: 12%; text-align: right" title="Revenue">12,287,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zjkmOf0nEMle" style="width: 12%; text-align: right" title="Revenue">10,971,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zVbwuDJi2MRa" style="width: 12%; text-align: right" title="Revenue">36,108,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zfrwEQ4Zrb3c" style="width: 12%; text-align: right" title="Revenue">31,335,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Hospital</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HospitalMember_zs8rQmfE2Uv3" style="text-align: right" title="Revenue">783,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HospitalMember_zSHzwlrkZtD7" style="text-align: right" title="Revenue">440,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HospitalMember_zDbBGUTMI8u7" style="text-align: right" title="Revenue">1,909,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HospitalMember_zMkyeMYnUXqe" style="text-align: right" title="Revenue">1,420,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Homecare distributor</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_z2wSBiYErAc8" style="text-align: right" title="Revenue">524,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zI6WKVFbCvo9" style="text-align: right" title="Revenue">501,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_zOp5lICpib6f" style="text-align: right" title="Revenue">1,377,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareDistributorMember_z2kg54hFSkVf" style="text-align: right" title="Revenue">1,391,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Other</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--OtherMember_zhoJvfEKJhwg" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">277,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--OtherMember_zeTuaNLyXpT4" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">156,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--OtherMember_z2c5IYzhqtB3" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">490,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--OtherMember_ztygcsdQfLu1" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">309,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331_z35ClQhHsqB" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">13,871,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331_z0826JTQ8ZCf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">12,068,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331_znGpZ9RH45wd" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">39,884,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331_zMVXCTUgn2L8" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">34,455,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> In the following table, net homecare revenue is disaggregated by payer type: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Three Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31,</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 40%">Commercial</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_z3FshHLLZox2" style="width: 12%; text-align: right" title="Revenue">5,974,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zNztYVFAd3Pl" style="width: 12%; text-align: right" title="Revenue">4,787,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_zyNGIuB06hmg" style="width: 12%; text-align: right" title="Revenue">17,684,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 3%; text-align: left">$</td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--CommercialMember_z9OHZZ3bdRJ4" style="width: 10%; text-align: right" title="Revenue">12,706,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medicare</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zlblrwdW41q6" style="text-align: right" title="Revenue">4,825,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zf8Q92XH3asg" style="text-align: right" title="Revenue">4,544,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_znu5G9A0D17f" style="text-align: right" title="Revenue">13,666,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareMember_zEpFbPGThO28" style="text-align: right" title="Revenue">13,753,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Medicare Supplemental</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_zUOuGSlWrbc1" style="text-align: right" title="Revenue">1,177,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_zx5rK7eSEQa5" style="text-align: right" title="Revenue">1,278,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_zRBBvfjCBuCl" style="text-align: right" title="Revenue">3,447,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicareSupplementalMember_ztr8sQ6lYtI7" style="text-align: right" title="Revenue">3,681,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Medicaid</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zDCA42myitga" style="text-align: right" title="Revenue">115,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zX1X0Z3IedM1" style="text-align: right" title="Revenue">128,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_z2mzwLbUhqKd" style="text-align: right" title="Revenue">722,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--MedicaidMember_zgLZqDy147rf" style="text-align: right" title="Revenue">618,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt">Other homecare</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zZqv2Ugx4Zo7" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">196,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zqUDOsiDoHib" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">234,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zkok32gUOPBi" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">589,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember__custom--PayerTypeAxis__custom--OtherHomecareMember_zVHqwBbfGow6" style="border-bottom: Black 1pt solid; text-align: right" title="Revenue">577,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20240101__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zodYspyRdxWa" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">12,287,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_zHypqSaYIDz1" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">10,971,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230701__20240331__srt--ProductOrServiceAxis__custom--HomeCareMember_zmbXcUVQfHW2" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">36,108,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220701__20230331__srt--ProductOrServiceAxis__custom--HomeCareMember_z7WOy74kQurf" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue">31,335,000</td><td style="text-align: left; padding-bottom: 2.5pt"> </td></tr> </table> 12287000 10971000 36108000 31335000 783000 440000 1909000 1420000 524000 501000 1377000 1391000 277000 156000 490000 309000 13871000 12068000 39884000 34455000 5974000 4787000 17684000 12706000 4825000 4544000 13666000 13753000 1177000 1278000 3447000 3681000 115000 128000 722000 618000 196000 234000 589000 577000 12287000 10971000 36108000 31335000 Contract balances. The following table provides information about contract assets from contracts with customers: Schedule of contract asset <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (decrease)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Increase (decrease)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Contract assets, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_dxL_c20230701__20240331_zv1oZBnygtk9" style="width: 12%; text-align: right" title="Contract assets beginning::XDX::487000">487,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--ContractWithCustomerAssetNetCurrent_iS_dxL_c20220701__20230630_zuBZqz1paEH5" style="width: 12%; text-align: right" title="Contract assets beginning::XDX::487000">286,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Reclassification of contract assets to accounts receivable</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20230701__20240331_z64D1L1GMXt8" style="text-align: right" title="Reclassification of contract assets to accounts receivable">(1,453,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--ContractWithCustomerAssetReclassifiedToReceivable_c20220701__20230630_z4ZnjKHBxxjj" style="text-align: right" title="Reclassification of contract assets to accounts receivable">(1,220,000</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Contract assets recognized</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20230701__20240331_z2DTtAMTRyJb" style="text-align: right" title="Contract assets recognized">1,829,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_98A_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220701__20230630_zMmjjLmb51mi" style="text-align: right" title="Contract assets recognized">1,351,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Increase (decrease) as a result of changes in the estimate of amounts to be realized from payers, excluding amounts transferred to receivables during the period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20230701__20240331_zYPKAt8T7Fji" style="border-bottom: Black 1pt solid; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period">(221,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_c20220701__20230630_ztHIeWI5cINi" style="border-bottom: Black 1pt solid; text-align: right" title="Increase (decrease) as a result of changes in the estimate of amounts to be realized frompayers, excluding amounts transferred to receivables during the period">70,000</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="padding-bottom: 2.5pt">Contract assets, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20230701__20240331_z6M1GXpOeKKd" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract assets, ending">642,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--ContractWithCustomerAssetNetCurrent_iE_c20220701__20230630_zYeC1LQ8Bud3" style="border-bottom: Black 2.5pt double; text-align: right" title="Contract assets, ending">487,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> -1453000 -1220000 1829000 1351000 -221000 70000 642000 487000 Note 3. Inventories The components of inventory were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zXkeiDSpjvIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230630_z9YWvdCuflpl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherInventorySupplies_iI_zwx8Vm8RmnPd" style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Parts inventory</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,016,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,420,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_zr8DhtLe1Oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">449,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">470,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_zOsDKaeewaf3" style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">856,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherInventoryInTransit_iI_zDYVyFTYQJ0b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Estimated inventory to be returned</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_zXd6kntPVu2d" style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt">Less: Reserve for obsolescence</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(403,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(257,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--InventoryNet_iI_zaCTzm3knb9b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,178,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,221,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The components of inventory were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20240331_zXkeiDSpjvIe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20230630_z9YWvdCuflpl" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40A_eus-gaap--OtherInventorySupplies_iI_zwx8Vm8RmnPd" style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Parts inventory</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,016,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">3,420,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--InventoryWorkInProcess_iI_zr8DhtLe1Oj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">449,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">470,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--InventoryFinishedGoods_iI_zOsDKaeewaf3" style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">856,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherInventoryInTransit_iI_zDYVyFTYQJ0b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Estimated inventory to be returned</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">265,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryValuationReserves_iNI_di_zXd6kntPVu2d" style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt">Less: Reserve for obsolescence</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(403,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(257,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--InventoryNet_iI_zaCTzm3knb9b" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,178,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,221,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 3016000 3420000 449000 470000 856000 323000 260000 265000 403000 257000 4178000 4221000 Note 4. Warranty Reserve The Company provides a lifetime warranty on its products to the prescribed patient for sales within the U.S. and a three-year warranty for all hospital sales and sales to individuals outside the U.S. The Company estimates the costs that may be incurred under its warranty and records a liability in the amount of such costs at the time the product is shipped. Factors that affect the Company’s warranty reserve include the number of units shipped, historical and anticipated rates of warranty claims, the product’s useful life and cost per claim. The Company periodically assesses the adequacy of its recorded warranty reserve and adjusts the amounts as necessary. Changes in the Company’s warranty reserve were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Warranty reserve, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iS_c20230701__20240331_zIkvpH9BbiNk" style="width: 12%; text-align: right" title="Warranty reserve, beginning">1,378,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230630_zKJ7V7e81eDg" style="width: 12%; text-align: right" title="Warranty reserve, beginning">1,256,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Accrual for products sold</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20230701__20240331_zRRXkwswj9z1" style="text-align: right" title="Accrual for products sold">426,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230630_zBYybujNw5D3" style="text-align: right" title="Accrual for products sold">416,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Expenditures and costs incurred for warranty claims</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20230701__20240331_z9vgRvWoiUFd" style="border-bottom: Black 1pt solid; text-align: right" title="Expenditures and costs incurred for warranty claims">(279,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230630_zcOyXz5WZjH8" style="border-bottom: Black 1pt solid; text-align: right">(294,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warranty reserve, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProductWarrantyAccrual_iE_c20230701__20240331_znH6eI0HoUXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warranty reserve, ending">1,525,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230630_zQGD3kXPDKI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warranty reserve, ending">1,378,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Changes in the Company’s warranty reserve were as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31, 2024</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended June 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Warranty reserve, beginning</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--ProductWarrantyAccrual_iS_c20230701__20240331_zIkvpH9BbiNk" style="width: 12%; text-align: right" title="Warranty reserve, beginning">1,378,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--ProductWarrantyAccrual_iS_c20220701__20230630_zKJ7V7e81eDg" style="width: 12%; text-align: right" title="Warranty reserve, beginning">1,256,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Accrual for products sold</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20230701__20240331_zRRXkwswj9z1" style="text-align: right" title="Accrual for products sold">426,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ProductWarrantyAccrualWarrantiesIssued_c20220701__20230630_zBYybujNw5D3" style="text-align: right" title="Accrual for products sold">416,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Expenditures and costs incurred for warranty claims</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_980_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20230701__20240331_z9vgRvWoiUFd" style="border-bottom: Black 1pt solid; text-align: right" title="Expenditures and costs incurred for warranty claims">(279,000</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ProductWarrantyAccrualPayments_iN_di_c20220701__20230630_zcOyXz5WZjH8" style="border-bottom: Black 1pt solid; text-align: right">(294,000</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Warranty reserve, ending</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_eus-gaap--ProductWarrantyAccrual_iE_c20230701__20240331_znH6eI0HoUXh" style="border-bottom: Black 2.5pt double; text-align: right" title="Warranty reserve, ending">1,525,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--ProductWarrantyAccrual_iE_c20220701__20230630_zQGD3kXPDKI7" style="border-bottom: Black 2.5pt double; text-align: right" title="Warranty reserve, ending">1,378,000</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 1378000 1256000 426000 416000 279000 294000 1525000 1378000 Note 5. Income Taxes Income tax expense was estimated at $468,000 and $1,217,000, and the effective tax rate was 23.9% and 26.8% for the three and nine months ended March 31, 2024, respectively. Estimated income tax expense for the three and nine months ended March 31, 2024, includes a discrete current tax benefit of $99,000 and $95,000, respectively, primarily related to the exercise of stock options. Income tax expense was estimated at $147,000 and $418,000, and the effective tax rate was 12.0% and 16.4% for the three and nine months ended March 31, 2023, respectively. Estimated income tax expense for the three and nine months ended March 31, 2023, includes a discrete current tax benefit of $176,000 and $219,000, respectively, related to the exercise of stock options. The Company is subject to U.S. federal and state income tax in multiple jurisdictions. With limited exceptions, years prior to the Company’s fiscal year ended June 30, 2020, are no longer open to U.S. federal, state or local examinations by taxing authorities. The Company is not under any current income tax examinations by any federal, state or local taxing authority. If any issues addressed in the Company’s tax audits are resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income taxes in the period such resolution occurs. 468000 1217000 0.239 0.268 99000 95000 0.120 0.164 176000 219000 Note 6. Financing Arrangements The Company has a credit facility that provides for a $<span id="xdx_905_eus-gaap--LineOfCreditFacilityMaximumBorrowingCapacity_iI_c20240331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zeXBGYtaoCMh" title="Maximum borrowing capacity">2,500,000 revolving line of credit through December 18, 2025, if not renewed before such date. There was no outstanding principal balance on the line of credit as of March 31, 2024, or June 30, 2023. Interest on borrowings under the line of credit, if any, accrues at the prime rate (<span id="xdx_906_ecustom--PrimeRate_iI_pid_dp_uPure_c20240331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember__us-gaap--VariableRateAxis__us-gaap--PrimeRateMember_zIddY5qVVM78" title="Interest rate">8.50% on March 31, 2024) less <span id="xdx_90A_eus-gaap--DebtInstrumentBasisSpreadOnVariableRate1_pid_dp_uPure_c20230701__20240331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_znVOOfO8NMFj" title="Basis spread on rate">1.00% and is payable monthly. The amount eligible for borrowing on the line of credit is limited to the lesser of $<span id="xdx_909_eus-gaap--LineOfCreditFacilityCapacityAvailableForSpecificPurposeOtherThanForTradePurchases_iI_c20240331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zVUIWpiVSxUl" title="Available borrowing capacity">2,500,000 or <span id="xdx_90A_ecustom--BorrowingCapacityOfEligibleAccountsReceivablePercent_iI_dp_uPure_c20240331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zncvg3l5ztSe" title="Borrowing capacity of eligible accounts receivable percent">57.00% of eligible accounts receivable. On March 31, 2024, the maximum $<span id="xdx_902_eus-gaap--LineOfCreditFacilityRemainingBorrowingCapacity_iI_c20240331__us-gaap--LineOfCreditFacilityAxis__us-gaap--RevolvingCreditFacilityMember_zt9cELfP0PJj" title="Available borrowing capacity">2,500,000 was eligible for borrowing. Payment obligations under the line of credit, if any, are secured by a security interest in substantially all the tangible and intangible assets of the Company. The documents governing the line of credit contain certain financial and non-financial covenants that include a minimum tangible net worth covenant of not less than $10,125,000 and restrictions on the Company’s ability to incur certain additional indebtedness or pay dividends. 2500000 0.0850 0.0100 2500000 0.5700 2500000 10125000 Note 7. Common Stock Authorized shares: The Company’s Articles of Incorporation, as amended, have established 15,000,000 authorized shares of capital stock consisting of 13,000,000 shares of common stock, par value $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_iI_pid_uUSDPShares_c20240331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zeBcI0JXoV9d" title="Common stock, par value (in dollars per share)">0.01 per share, and <span id="xdx_90E_eus-gaap--CommonStockSharesAuthorized_iI_pid_uShares_c20240331__us-gaap--StatementClassOfStockAxis__custom--AuthorizedSharesUndesignatedStockMember_z7JG0bP7Rme3" title="Common stock, authorized">2,000,000 shares of undesignated stock. On May 26, 2021, the Company’s Board of Directors (the “Board”) approved a stock repurchase authorization. Under the authorization, the Company was originally able to repurchase up to $<span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_iI_pid_dxL_uShares_c20220526__srt--TitleOfIndividualAxis__srt--BoardOfDirectorsChairmanMember_zI1MECSgvjEa" title="Common stock, authorized::XDX::3000000">3.0 million of shares of common stock through May 26, 2022. On May 26, 2022, the Board removed the date limitation. As of March 31, 2024, a total of 239,995 shares have been repurchased and retired under this authorization for a total cost of $2,725,000, or $11.36 per share. Repurchased shares have been retired and constitute authorized but unissued shares. There were no share repurchases for the three and nine months ended March 31, 2024. 15000000 13000000 0.01 2000000 239995 2725000 11.36 <p id="xdx_80A_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zOXfMTMIGVTh" style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Note 8. Share-Based Compensation The Company’s share-based compensation plans are described in Note 8 to the financial statements included in the Company’s Annual Report on Form 10-K for fiscal 2023. Share-based compensation expense was $1,250,000 and $506,000 for the nine months ended March 31, 2024, and 2023, respectively. This expense is included in selling, general and administrative expense in the Condensed Statements of Operations. Stock Options <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zumnIQK8uPSj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price per Share</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Outstanding on June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zE70uOCO53cl" style="width: 12%; text-align: right" title="Option outstanding , beginning">451,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zME4QujcTkbg" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning">6.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWCmIaLwt0qh" style="text-align: right" title="Granted">263,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyWSVooyBUol" style="text-align: right" title="Granted">10.70</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-left: 0.125in">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3A8sKHmYWzf" style="text-align: right" title="Exercised">(56,063</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOCLj6Aa1j58" style="text-align: right" title="Exercised">5.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cancelled or Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z400WmW0SxNb" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or Forfeited">(21,079</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpCMN0jMArKb" style="text-align: right" title="Cancelled or Forfeited">10.46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding on March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS4dqLYVfTz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending">637,590</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi2wxlJ37fdd" style="text-align: right" title="Weighted average grant date fair value, ending">8.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zX5dp4CSbCH2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following assumptions were used to estimate the fair value of stock options granted: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended June 30, 2023</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230701__20240331_zVgI5ZwIXkqc" title="Risk free interest rate - minimum">3.85 – <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230701__20240331_zpT5bIFLny13" title="Risk free interest rate - maximum">4.64%</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230630_zpKEHP2lyrKc" title="Risk free interest rate - minimum">2.88 - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230630_zJEBSINnZ0A9" title="Risk free interest rate - maximum">4.23%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left">Expected term (years)</td><td style="width: 1%"> </td> <td style="width: 13%; text-align: center">6</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: center">6</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230701__20240331_zcQ0pAiDt9Wj" title="Expected volatility - maximum">51 - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230701__20240331_zO03QdZM8Jf2" title="Expected volatility - maximum">53%</td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230630_zdxHq7Od5VXb" title="Expected volatility - maximum">53% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230630_ztJoWmdSrCqi" title="Expected volatility - maximum">54%</td> <td> </td></tr> </table> The intrinsic value of an option is the amount by which the fair value of the underlying stock exceeds its exercise price. On March 31, 2024, the weighted average remaining contractual term for all outstanding stock options was <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtxL_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXXOKnLWKhw8" title="Weighted average contractual term outstanding stock options::XDX::P6Y8M12D">6.7 years and the aggregate intrinsic value of the options was $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zs6POasDePM3" title="Options exercisable, intrinsic value">4,878,000. Outstanding on March 31, 2024, were 637,590 stock options issued to employees, of which <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6lSl0jwIEDa" title="Vested and exercisable">319,088 were vested and exercisable and had an aggregate intrinsic value of $<span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iI_c20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zSDkFfNWHh92" title="Options exercisable, intrinsic value">3,118,000. As of March 31, 2024, $925,000 of total unrecognized compensation expense related to stock options is expected to be recognized over a weighted-average period of approximately <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtxL_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zRnw05cKMxPj" title="Unrecognized compensation expense, period for recognition::XDX::P2Y9M18D">2.8 years. Restricted Stock During the nine months ended March 31, 2024, the Company issued restricted stock awards to employees totaling <span id="xdx_907_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zJ4bQe5k0bVg" title="Stock issued">23,428 shares of common stock, with a weighted average vesting term of <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dxL_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zmn6n0VKYtw6" title="Vesting term::XDX::P3Y">3.0 years and a weighted average fair value of $<span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__us-gaap--PlanNameAxis__custom--EmployeeMember_zzFVPVgDvspk" title="Fair value of per share">10.74 per share, and to directors totaling <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_z9NCUcj4AWW9" title="Stock issued">21,000 shares of common stock, with a vesting term of six months and a weighted average fair value of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember__srt--TitleOfIndividualAxis__srt--DirectorMember_zj0fyAiGJbqh" title="Fair value of per share">10.44 per share. There were <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_pid_uShares_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zKraAHLXYng3" title="Restricted stock - unvested">57,661 shares of unvested restricted stock with a weighted average fair value of $<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_pid_uUSDPShares_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zR3mgjZdttT2" title="Weight average fair value - unvested restricted stock (per share)">10.53 per share outstanding as of March 31, 2024. As of March 31, 2024, $253,000 of total unrecognized compensation expense related to restricted stock awards is expected to be recognized over a weighted-average period of approximately <span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtxL_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z8XDS63bw4Hl" title="Unrecognized compensation expense, period for recognition::XDX::P1Y4M24D">1.6 years. Performance-Based Restricted Stock Units The Company granted <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_z88J7hgo9uv2" title="Shares granted">175,000 performance-based restricted stock units (“PSUs”) to our CEO in connection with his appointment as CEO on July 1, 2023. The PSUs are to be earned based on the extent to which performance goals tied to Total Shareholder Return (“TSR”) are achieved. <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationDescriptionAndTerms_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_ztOIC0y16XR1" title="Other description">The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. The grant date fair value of the awards was determined using a Monte Carlo valuation model with an expected term of four years. Stock based compensation expense recognized for PSUs was $217,000 and $0 for the nine months ended March 31, 2024, and 2023, respectively. The weighted average grant date fair value per unit was $<span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zvYxalwuk8G8" title="Fair value of per share">6.58 and as of March 31, 2024, there are <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_pid_uShares_c20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zVDqIu8WSsdg" title="Shares outstanding">175,000 PSUs outstanding. On March 31, 2024, there was approximately $935,000 of total unrecognized compensation expense related to outstanding PSUs that is expected to be recognized over a period of <span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtxL_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockUnitsRSUMember_zGttNv6pjUN" title="Unrecognized compensation expense, period for recognition::XDX::P3Y2M30D">3.25 years. 1250000 506000 <p id="xdx_890_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zumnIQK8uPSj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Stock option transactions during the nine months ended March 31, 2024, are summarized as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted-Average Exercise Price per Share</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="width: 70%; text-align: left">Outstanding on June 30, 2023</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zE70uOCO53cl" style="width: 12%; text-align: right" title="Option outstanding , beginning">451,570</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iS_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zME4QujcTkbg" style="width: 12%; text-align: right" title="Weighted average grant date fair value, beginning">6.93</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-left: 0.125in">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zWCmIaLwt0qh" style="text-align: right" title="Granted">263,162</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zyWSVooyBUol" style="text-align: right" title="Granted">10.70</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-left: 0.125in">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z3A8sKHmYWzf" style="text-align: right" title="Exercised">(56,063</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOCLj6Aa1j58" style="text-align: right" title="Exercised">5.45</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt; padding-left: 0.125in">Cancelled or Forfeited</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z400WmW0SxNb" style="border-bottom: Black 1pt solid; text-align: right" title="Cancelled or Forfeited">(21,079</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zpCMN0jMArKb" style="text-align: right" title="Cancelled or Forfeited">10.46</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left; padding-bottom: 2.5pt">Outstanding on March 31, 2024</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zS4dqLYVfTz7" style="border-bottom: Black 2.5pt double; text-align: right" title="Option outstanding, ending">637,590</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_iE_pid_uUSDPShares_c20230701__20240331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zi2wxlJ37fdd" style="text-align: right" title="Weighted average grant date fair value, ending">8.50</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 451570 6.93 263162 10.70 56063 5.45 21079 10.46 637590 8.50 <p id="xdx_895_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zX5dp4CSbCH2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following assumptions were used to estimate the fair value of stock options granted: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Nine Months Ended March 31, 2024</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Fiscal Year Ended June 30, 2023</td> <td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Risk-free interest rate</td><td> </td> <td style="text-align: center"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20230701__20240331_zVgI5ZwIXkqc" title="Risk free interest rate - minimum">3.85 – <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20230701__20240331_zpT5bIFLny13" title="Risk free interest rate - maximum">4.64%</td><td> </td> <td style="text-align: center"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_pid_dp_uPure_c20220701__20230630_zpKEHP2lyrKc" title="Risk free interest rate - minimum">2.88 - <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_pid_dp_uPure_c20220701__20230630_zJEBSINnZ0A9" title="Risk free interest rate - maximum">4.23%</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 70%; text-align: left">Expected term (years)</td><td style="width: 1%"> </td> <td style="width: 13%; text-align: center">6</td><td style="width: 2%"> </td> <td style="width: 13%; text-align: center">6</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(214,243,232)"> <td style="text-align: left">Expected volatility</td><td> </td> <td style="text-align: center"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20230701__20240331_zcQ0pAiDt9Wj" title="Expected volatility - maximum">51 - <span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20230701__20240331_zO03QdZM8Jf2" title="Expected volatility - maximum">53%</td><td> </td> <td style="text-align: center"><span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20220701__20230630_zdxHq7Od5VXb" title="Expected volatility - maximum">53% - <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20220701__20230630_ztJoWmdSrCqi" title="Expected volatility - maximum">54%</td> <td> </td></tr> </table> 0.0385 0.0464 0.0288 0.0423 0.51 0.53 0.53 0.54 4878000 637590 319088 3118000 925000 23428 10.74 21000 10.44 57661 10.53 253000 175000 The performance-based restricted stock units will be eligible to vest and settle into shares of common stock on a 1-for-1 basis with respect to one-half of the shares upon achieving a total shareholder return of 50% and the remaining shares upon a total shareholder return of 100%, in each case within four years of the date of grant. The grant date fair value of the awards was determined using a Monte Carlo valuation model with an expected term of four years. 217000 0 6.58 175000 935000 Note 9. Commitments and Contingencies The Company is occasionally involved in claims and disputes arising in the ordinary course of business. The Company insures certain business risks where possible to mitigate the financial impact of individual claims and establishes reserves for an estimate of any probable cost of settlement or other disposition.